



(86) Date de dépôt PCT/PCT Filing Date: 2016/02/26
(87) Date publication PCT/PCT Publication Date: 2016/09/01
(85) Entrée phase nationale/National Entry: 2017/08/11
(86) N° demande PCT/PCT Application No.: US 2016/019852
(87) N° publication PCT/PCT Publication No.: 2016/138425
(30) Priorités/Priorities: 2015/02/26 (US62/121,379);
2015/10/26 (US62/246,455); 2015/10/27 (US62/247,099)

(51) Cl.Int./Int.Cl. *A61K 31/505* (2006.01),
A61K 31/7042 (2006.01), *A61K 31/7068* (2006.01)

(71) Demandeur/Applicant:
UNIVERSITY OF KENTUCKY RESEARCH
FOUNDATION, US

(72) Inventeurs/Inventors:
AMBATI, JAYAKRISHNA, US;
FOWLER, BENJAMIN, US;
AMBATI, KAMESHWARI, US

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : COMPOSITIONS ET METHODES POUR LE TRAITEMENT DE DEGRADATIONS DE LA RETINE
(54) Title: COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION




FIG. 1

(57) **Abrégé/Abstract:**


The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation / retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2016/138425 A1

(43) International Publication Date

1 September 2016 (01.09.2016)

(51) International Patent Classification:

A61K 31/505 (2006.01) A61K 31/7068 (2006.01)

A61K 31/7042 (2006.01)

(21) International Application Number:

PCT/US2016/019852

(22) International Filing Date:

26 February 2016 (26.02.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/121,379 26 February 2015 (26.02.2015) US

62/246,455 26 October 2015 (26.10.2015) US

62/247,099 27 October 2015 (27.10.2015) US

(71) Applicant: UNIVERSITY OF KENTUCKY RE-SEARCH FOUNDATION [US/US]; 201 Gillis Building, Lexington, KY 40506-0033 (US).

(72) Inventors: AMBATI, Jayakrishna; 740 S. Limestone, Lexington, KY 40536-0284 (US). FOWLER, Benjamin; 201 Gillis Building, Lexington, KY 40506-0033 (US). AMBATI, Kameshwari; 740 S. Limestone, Lexington, KY 40536-0284 (US).

(74) Agents: DECKER, Mandy, Wilson et al.; Suite 800, 401 Commerce Street, Nashville, TN 37219 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION




FIG. 1

(57) **Abstract:** The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation / retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.

WO 2016/138425 A1

COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION

RELATED APPLICATIONS

[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application Nos. 62/247,099, filed October 27, 2015; 62/246,455, filed October 26, 2015; and 62/121,379, filed February 26, 2015, the entire disclosures of which are incorporated herein by this reference.

TECHNICAL FIELD

[0002] The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation / retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure relates to compounds and compositions comprising a nucleoside and/or a nucleoside reverse transcriptase inhibitor (NRTI).

BACKGROUND

[0003] Geographic atrophy, an advanced form of age-related macular degeneration that causes blindness in millions of people worldwide and for which there is no approved treatment, results from death of retinal pigmented epithelium (RPE) cells. For example, expression of DICER, an enzyme involved in microRNA (miRNA) biogenesis, is reduced in the RPE of human eyes with geographic atrophy, and that conditional ablation of *Dicer1* induces RPE degeneration in mice. Surprisingly, ablation of seven other enzymes responsible for miRNA biogenesis or function does not induce such pathology. Instead, knockdown of *DICER1* leads to accumulation of *Alu* repeat RNA in human RPE cells and of B1 and B2 (*Alu*-like elements) repeat RNAs in the RPE of mice. *Alu* RNA is dramatically increased in the RPE of human eyes with geographic atrophy, and introduction of this pathological RNA induces death of human RPE cells and RPE degeneration in mice.

[0004] Age-related macular degeneration (AMD), which is as prevalent as cancer in industrialized countries, is a leading cause of blindness worldwide. In contrast to the neovascular form of AMD, for which many approved treatments exist, the far more common atrophic form of AMD remains poorly understood and without effective clinical intervention. Extensive atrophy of the retinal pigment epithelium leads to severe vision loss and is termed geographic atrophy.

[0005] Hence, there remains a need for compositions and methods for treating retinal degradation / retinal degeneration, and particularly RPE degradation.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying drawings of which:

[0007] **FIG. 1** displays a top row of ocular fundus photographs of mice receiving control PBS, or *Alu* RNA treatment, with or without increasing amounts of d4T (left to right); and RPE flat mounts, stained for intercellular junctions (ZO-1) in red that are disrupted upon *Alu* RNA administration but that are restored to healthy RPE morphology/intercellular junctions at highest dose of d4T.

[0008] FIG. 2 provides a bar graph showing that human (HeLa) cells treated with an enforced expression plasmid for Alu RNA (pAluA) for denoted amounts of time exhibited profoundly reduced viability compared to a null plasmid (pUC19), as monitored by MTS proliferation assay and that d4T co-administration prevented cell death induced by Alu overexpression.

[0009] FIG. 3 shows the results of Northern blotting using an Alu-specific probe. As presented in FIG. 3, primary human RPE cells treated with antisense oligonucleotides targeting DICER1 (Der as) (lane 3 (third lane from left)) show increased Alu RNA levels in the nuclear compartment compared to control antisense oligonucleotides (Ctr as) (lane 1 (leftmost)), and co-administration of d4T (lanes 2 and 4) does not reduce Alu RNA levels. u6 (bottom row) is shown as a loading control for nuclear fraction.

[0010] FIG. 4 provides another example of the results of Northern blotting using an Alu-specific probe. As presented in FIG. 4, co-administration of d4T does not change Alu RNA levels at 1, 4, or 24 hours after transfection in the nuclear fraction of human RPE cells transfected with Alu RNA, with or without d4T, as detected by Northern blotting using an Alu-specific probe. u6 (bottom row) is shown as loading control for nuclear fraction in FIG. 4.

[0011] FIG. 5 provides the results of a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (top, middle lane, lower band), which is blocked by co-treatment with d4T (100 uM; rightmost lane). The bottom row is a vinculin loading control.

[0012] FIG. 6 is a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (top, middle lane, lower band), which is blocked with co-treatment with 3TC (20-100 uM; rightmost lane), wherein the lowermost band is the loading control, vinculin.

[0013] FIG. 7 is a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (top, middle lane, lower band), which is blocked with co-treatment with azidothymidine (AZT), cordycepin, and abacavir (ABC) (50-100 uM; lanes 3-8 from left). The loading control vinculin is shown on the bottom.

[0014] FIG. 8 provides a gel showing that primary human RPE cells treated with LPS/ATP, a classic inflammasome activator, exhibit increased Casp-1 activation, and phosphorylation of IRAK4, which is also a marker of inflammasome signaling via the cell surface receptor adaptor protein MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM)

blocks Casp-1 activation and IRAK4 phosphorylation induced by LPS/ATP. Vinculin was used as the loading control in the gel of FIG. 8. Additionally, as shown, LPS and ATP activate the NLRP3 inflammasome only in combination.

[0015] FIG. 9 provides the results of Western blotting, wherein d4T, 3TC, and cordycepin (at 100 μ M), all di-deoxy nucleoside reverse transcriptase inhibitors, are shown to inhibit Caspase-1 activation (active p20 band, top) and IL-18 maturation (bottom) induced by LPS/ATP. To produce FIG. 9, cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/ATP treatment of mouse bone marrow-derived macrophages and run on Western blotting probing with antibodies for Caspase-1 and IL-18.

[0016] FIG. 10 provides the result of a Western blot showing that d4T (100, 250 μ M) inhibits IL-1 beta maturation (top, 18 and 22 kDa forms) and Caspase-1 activation (active p20 band, bottom) induced by nigericin. To produce FIG. 10, cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/nigericin treatment of mouse bone marrow-derived macrophages and run on Western blotting probing with antibodies for IL-1 beta and Caspase-1.

[0017] FIG. 11 shows a bar graph illustrating that d4T does not inhibit IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by monosodium urate (MSU). FIG. 11 was created after human THP-1 monocytes were differentiated into macrophages with PMA, and, as shown in FIG. 11, treatment with MSU, a known inflammasome activator, increased IL-1 beta secretion compared to non-treated cells, whereas d4T co-administration at a range of doses (25-1000 μ M) did not significantly affect IL-1 beta secretion.

[0018] FIG. 12 is a bar graph, which shows that d4T and other nucleoside reverse transcriptase inhibitors do not inhibit IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. Human THP-1 monocytes were differentiated into macrophages with PMA. Their treatment with MSU increased IL-1 beta secretion compared to non-treated cells, as shown in FIG. 12, while co-administration of d4T, 3TC, or cordycepin (all are di-deoxy nucleotide analogs) at a range of doses (25-1000 μ M) did not significantly affect IL-1 beta secretion.

[0019] FIG. 13 is a graph, which provides that d4T reduces NLRP3 priming induced by Alu RNA. Indeed, as shown in FIG. 13, Alu RNA transfection increases NLRP3 mRNA levels in primary human RPE cells at 16 hours, an event termed "priming" (Y-axis) compared to mock (transfection reagent alone). This effect is blunted by co-administration of d4T (100 μ M) and normalized to 18S RNA control.

[0020] FIG. 14 illustrates, in graph format, that Alu RNA transfection increases IL-1 beta mRNA levels in primary human RPE cells at 24 hours, an event termed “priming”, (Y-axis) compared to mock (transfection reagent alone). This effect is blunted by co-administration of d4T (100 uM) and normalized to 18S RNA control.

[0021] FIG. 15 shows that d4T reduces mitochondrial ROS caused by Alu expression. Indeed, FIG. 15 demonstrates that enforced expression of Alu (pAluA) causes increased mitochondrial reactive oxygen species (mtROS), as detected by MitoSox assay. In order to produce FIG. 15, primary human RPE cells were incubated with Alu expressing plasmid or control plasmid (pUC19) with or without d4T. After 15 hours cells were co-stained for mtROS (red) and for cell count, nuclei (blue; Hoechst DNA stain). Cells in the pAluA group exhibited greater mtROS staining (red) compared to pUC19 control, an effect that is reduced in pAluA + d4T treated cells.

[0022] FIG. 16 provides a graph showing that d4T does not inhibit ATP release induced by Alu RNA. Moreover, primary human RPE cells treated with Alu RNA, for the times indicated in FIG. 16, release ATP. Cell culture supernatant was collected from mock or Alu RNA treated cells, with or without d4T, and ATP was detected using an ATP-dependent luciferase assay. Notably, d4T did not affect ATP release.

[0023] FIG. 17 shows that d4T reduces ATP-induced cell permeability to Yo-Pro1 (P2X7 receptor assay). Indeed, d4T dose-dependently reduced Yo-Pro entry induced by ATP, determined by an area-scan fluorescent measurement in a 96 well microplate reader. FIG. 17 provides the results of the fluorescence measurement in relative fluorescence units (RFU, y-axis).

[0024] FIG. 18 illustrates, in graph format, that d4T reduces extracellular potassium levels, which increase after Alu RNA transfection. Indeed, cell culture potassium levels increase in primary human RPE cells treated with Alu RNA for 6 hours, an effect that is reduced by d4T co-administration. Potassium levels were determined in cell culture supernatants spectrophotometrically using a potassium-dependent pyruvate kinase assay.

[0025] FIG. 19 shows that d4T blocks bzATP-induced cell permeability to Yo-Pro1 (P2X7 receptor assay). To prepare FIG. 19, d4T blocked YO-PRO-1 iodide entry in HEK293 cells stably expressing the human P2X7 receptor stimulated with the P2X7-selective agonist bzATP. Cells were pre-incubated with d4T for 30 minutes prior to addition of bzATP/YO-PRO, and fluorescence (in relative fluorescence units) at 485/515 nm was measured at t=30 minutes.

[0026] FIG. 20 provides a chemical structure of methoxy-d4T (me-d4T; IUPAC name: 1-[(2R,5S)-5-(methoxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione, also referred to herein “Kamuvudine 1”). More specifically, as shown in FIG. 20, a single substitution of the ribose 5' hydroxyl group of d4T with a methoxy group (circled) has been designed to prevent d4T phosphorylation.

[0027] FIG. 21 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA $\pm$ me-d4T.

[0028] FIG. 22 shows cells, wherein unmodified d4T, but not me-d4T, blocks replication of a GFP-expressing lentivirus in HeLa cells.

[0029] FIG. 23 provides a graph illustrating that unmodified d4T, but not me-d4T, reduces mtDNA levels (normalized to chromosomal DNA exon-intron junction sequence) in primary mouse RPE cells as determined by real-time quantitative PCR. $n=4$, $*p < 0.05$ by Student's t-test.

[0030] FIG. 24 provides flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Degeneration outlined by blue arrowheads. Representative images of $n = 4$ (B, C, E) shown. Scale bars, (C): 200 μ m; (E): 20 μ m.

[0031] FIG. 25 provides a schematic overview of me-d4T synthesis.

[0032] FIG. 26 is an HPLC chromatogram of me-d4T (peak # 6) final product, >97% purity.

[0033] FIG. 27 is a ^1H NMR spectroscopy of me-d4T final product, wherein the chemical shifts are consistent with the structure of me-d4T.

[0034] FIG. 28 provides the results of liquid chromatography/mass spectrometry of me-d4T final product, m/z ratio consistent with the structure of me-d4T.

[0035] FIG. 29 provides the methoxy variant of a nucleoside analog. The chemical structure of 3TC (2',3' dideoxycytidine) is shown, wherein the methoxy variation (O-methyl group) of nucleoside analog is circled.

[0036] FIG. 30 provides the methoxy variant of a nucleoside analog. The chemical structure of AZT (3'-azido-2',3'-dideoxythymidine) is shown, wherein the methoxy variation (O-methyl group) of nucleoside analog is circled.

[0037] FIG. 31 provides the methoxy variant of a nucleoside analog. The chemical structure of ABC (cyclopropylaminopurinylicyclopentene) is shown, wherein the methoxy variation (O-methyl group) of nucleoside analog is circled.

[0038] FIG. 32 shows a cell permeant variant of d4T (IC-d4T), where “n” group is equal to 11. Derivatives include cell permeant variants of 3TC, AZT, ABC, where the nucleobase

group (circled) may be replaced, in various embodiments, by 3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, ABC (FIG. 29-31), or derivatives thereof.

[0039] FIG. 33 provides the structure of an exemplary NRTI according to the present disclosure.

[0040] FIG. 34 is a Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in primary human RPE cells transfected with *Alu* RNA $\pm$ d4T.

[0041] FIG. 35 is a Western blot of Caspase-1 activation in human RPE cells transfected with *Alu* RNA $\pm$ NRTIs (3TC, AZT, ABC).

[0042] FIG. 36 includes fundus photographs: top row; flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Scale bars, 50 μ m.

[0043] FIG. 37 provides fundus photographs: top row; flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Scale bars, 50 μ m.

[0044] FIG. 38 illustrates that NRTIs block LPS/ATP-induced inflammasome activation. Specifically, FIG. 38 shows a gel indicating that d4T blocked Caspase-1.

[0045] FIG. 39 also illustrates that NRTIs block LPS/ATP-induced inflammasome activation, showing specifically a gel indicating that d4T blocked IL-1 beta.

[0046] FIG. 40 presents chromatograms showing that Raji TK⁺ cells, but not Raji TK⁻ cells, phosphorylate AZT to AZT-triphosphate (AZT-TP) as determined by liquid chromatography-mass spectrometry (LC-MS).

[0047] FIG. 41 shows that AZT blocks IL-1 beta activation by LPS/ATP in both Raji TK⁺ and TK⁻ cells, as determined by Western blot of cell lysates.

[0048] FIG. 42 is a bar graph illustrating that d4T does not block *Alu*-induced ATP release from primary human RPE cells (n=4).

[0049] FIG. 43 provides a graph of P2X7-mediated YO-PRO-1 dye uptake (fluorescence) induced by bzATP (100 μ M) in HEK293 cells stably expressing the human P2X7 receptor was inhibited by d4T and A438079 (64 μ M for both drugs). Fluorescence values are baseline subtracted from cells without bzATP treatment. * bzATP vs. d4T; # bzATP vs. A438079, p < 0.05 by Student-Newman Keuls post-hoc test (n = 12).

[0050] FIG. 44 is a Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in primary mouse RPE cells transfected with *Alu* RNA $\pm$ d4T.

[0051] FIG. 45 is a Northern blot of biotin-UTP-labeled *Alu* RNA-transfected primary human RPE cells.

[0052] FIG. 46 provides LC-MS/MS spectra of AZT-triphosphate (AZT-TP).

[0053] FIG. 47 provides LC-MS/MS spectra of AZU-triphosphate (AZT-TP).

[0054] FIG. 48 shows the chromatographic separation of Raji TK⁺ cells spiked with AZT-TP with MS spectra (inset) to confirm identity of designated peaks.

[0055] FIG. 49 shows the chromatographic separation of Raji TK⁺ cells spiked with AZU-TP with MS spectra (inset) to confirm identity of designated peaks.

[0056] FIG. 50 is a standard curve of AZT-TP standards (black circle). As shown, Raji TK⁺ samples treated with AZT produced AZT-TP (white triangles), whereas AZT-TP was not detectable in Raji TK⁺ cells treated with AZT.

[0057] FIG. 51 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with short peptide (Panx1¹⁰), which blocks P2X7 pore function but not cation flux (vs. scrambled peptide: Scr Panx1¹⁰).

[0058] FIG. 52 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with calmidazolium (FIG. 32 provides the chemical structure of IC- and EC-d4T used), which blocks P2X7 cation flux but not pore function.

[0059] FIG. 53 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with cell permeable (IC), cell-impermeable (EC), or unmodified (no tag) d4T.

[0060] FIG. 54 shows that d4T prevents pAlu-induced mitochondrial ROS generation in primary human RPE cells. In FIG. 54, mitochondrial reactive oxygen species (ROS) were visualized with MitoSox (Red) and cell nuclei with Hoechst (Blue).

[0061] Fig. 55 is a western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells in the presence of iron (III) ammonium citrate. The addition of TM-3TC (Structure 8) (25 μ M) blocked iron-induced Caspase-1 activation. Bottom: Loading control tubulin.

[0062] Fig. 56 is a western blot of Caspase-1 activation (p10 subunit) in primary human RPE cells in the presence of iron (III) ammonium citrate. The addition of d4T-ene (Structure 3) (25 μ M) blocked iron-induced Caspase-1 activation. Bottom: Loading control tubulin.

[0063] Fig. 57 is a western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells in the presence of iron (III) ammonium citrate. The addition of 2me-d4T (Structure 4) (25 μ M) blocked iron-induced Caspase-1 activation. Bottom: Loading control tubulin.

[0064] Fig. 58 is a western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA. The addition of d4T-ene (Structure 3) and TM-3TC (Structure 8) (25 and 100 μ M) blocked *Alu*-induced Caspase-1 activation. Bottom: Loading control tubulin.

[0065] Fig. 59 is a graph of the relative quantity of mtDNA in primary human RPE cells treated with NRTIs or derivatives (relative to vehicle treatment (DMSO), "No Tx") at a

concentration of 50 μ M for all drugs. DNA was collected after four days in cell culture with exposure to drug. Quantitative polymerase chain reaction was performed for mtDNA and normalized to genomic DNA sequence. Modified versions of d4T that are not phosphorylated (e.g. me-d4T (Fig. 20), 2 me-d4T (Structure 4)) do not exhibit mtDNA depletion compared to parental NRTI (d4T). TM-3TC is structure 8. N = 3-4/group, error bars are S.E.M.

[0066] Fig. 60 is a graph of the relative quantity of mtDNA in primary human RPE cells treated with NRTIs or derivatives (relative to vehicle treatment (DMSO), "No Tx") at a concentration of 50 μ M for all drugs. DNA was collected after four days in cell culture with exposure to drug. Quantitative polymerase chain reaction was performed for mtDNA and normalized to genomic DNA sequence. Modified versions of AZT that are not phosphorylated (me-AZT (Structure 1), N-Me-Me-AZT (Structure 10)) do not exhibit mtDNA depletion compared to parental compound (AZT). N = 3-4/group, error bars are S.E.M.

[0067] Fig. 61 displays a top row of ocular fundus photographs of mice receiving subretinal control empty-vector plasmid (pNull), or Alu RNA-expressing plasmid (pAlu), treated with twice daily intraperitoneal modified NRTIs (me-AZT (Structure 1), N-me-me-AZT (Structure 10), or 2 me-d4T (Structure 4); 25 mg/kg/administration) or control vehicle, and bottom row RPE flat mounts, stained for intercellular junctions (ZO-1) in red that are disrupted upon *Alu* RNA expression but that are restored to healthy RPE morphology/intercellular junctions with modified NRTI treatment. Scale bars 20 μ m.

[0068] Fig. 62 provides a schematic overview of the synthesis of Formula I (structure C in Scheme 1), Formula IV (structure B), Formula VIII (structure E), Formula X (structure D), and methoxy-d4T (structure A; also Fig. 20).

[0069] Fig. 63 is a graph of a lentivirus transduction assay showing that modified NRTIs do not block lentivirus replication (in contrast to NRTIs, which blocked lentivirus GFP expression). A GFP-expressing lentivirus was added to 2.5×10^3 HeLa cells at multiplicity of infection of 20 in the presence of NRTIs (AZT, 3TC, d4T), modified NRTIs (me-AZT, structure 1; 2me-AZT, structure 10; TM-3TC, structure 8; me-d4T, Fig. 20; 2me-d4T, structure 4), or control (vehicle). All drugs were added at a concentration of 10 μ M. Cells were imaged for GFP expression 72 hours after addition of lentivirus. GFP-positive cells per field of view were recorded. n = 4-11, error bars S.E.M. Reverse transcription of lentivirus is essential for GFP expression; modified NRTIs should not block reverse transcriptase, whereas NRTIs are known to block reverse transcriptase.

[0070] Fig. 64 is a bar graph showing results of an iGlucc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 3TC.

[0071] Fig. 65 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 3Me-3TC.

[0072] Fig. 66 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 3Et-3TC.

[0073] Fig. 67 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to AZT.

[0074] Fig. 68 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 2Me-AZT.

[0075] Fig. 69 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 2Et-AZT.

[0076] Fig. 70 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to d4T.

[0077] Fig. 71 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to O-Me N-Et d4T.

[0078] Fig. 72 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in response to Me-d4T.

[0079] Fig. 73 is a bar graph showing results of an iGluc cell luminescence assay, showing inhibition of Caspase-1 activation in a dose-dependent manner in response to 2Et-d4T.

[0080] Fig. 74 includes a series of western blots showing that Alu-RNA-induced caspase-1 activation is reduced by 2Et-d4T (25 μ M), 2Me-AZT (25 μ M), O-Me N-Et d4T (25 μ M), d4T-ene (25-100 μ M), and TM-3TC (25-100 μ M).

[0081] Fig. 75 includes a series of western blots showing that iron-induced caspase-1 activation is reduced by TM-3TC (25 μ M), d4T-ene (25 μ M), 2Me-d4T (25 μ M), Me-AZT (25-100 μ M), and 2Me-AZT (25 μ M). N=3-4.

[0082] Fig. 76 includes a western blot showing that Complement-induced Caspase-1 activation is reduced by 3TC (25 μ M).

[0083] Fig. 77 includes a western blot showing that Paraquat-induced Caspase-1 activation is reduced by 3TC (25 μ M).

[0084] Fig. 78 includes a western blot showing that Amyloid beta-induced Caspase-1 activation is reduced by 3TC (10-25 μ M).

[0085] Fig. 79 includes data showing choroidal neovascularization in a model of "wet AMD" is reduced by 3TC (0.55 nmol), ABC (0.64 nmol), or AZT (0.55 nmol).

[0086] Fig. 80 includes data showing choroidal neovascularization (CNV) in a model of "wet AMD" is reduced by Me-d4T, O-Me-N-Et-d4T, 2Et-AZT or 3Et-3TC (0.14 nmol).

[0087] Fig. 81 includes fundus photographs of the left eye (top two rows) and the right eye (bottom two rows) of a first mouse having pre-existing CNV lesions, the first and third row showing time dependent dye leakage from the CNV lesions, the second row showing time-dependent dye leakage after a single intravitreal administration of 125 ng of 3TC, and the fourth row showing time-dependent dye leakage after a single intravitreal administration of 62.5 ng of 3-Me-3TC.

[0088] Fig. 82 includes fundus photographs of the left eye (top two rows) and the right eye (bottom two rows) of a second mouse having pre-existing CNV lesions, the first and third row showing time dependent dye leakage from the CNV lesions, the second row showing time-dependent dye leakage after a single intravitreal administration of 125 ng of 3TC, and the fourth row showing time-dependent dye leakage after a single intravitreal administration of 62.5 ng of 3-Me-3TC.

[0089] Fig. 83 includes data showing Alu RNA-induced RPE degeneration in a model of "dry AMD" is blocked by 3Me-3TC and O-Me N-Et d4T.

[0090] Fig. 84 includes data showing pAlu-induced RPE degeneration in a model of "dry AMD" is blocked by 3Me-3TC.

[0091] Fig. 85 includes data showing pAlu-induced RPE degeneration in a model of "dry AMD" is blocked by 3Et-3TC.

[0092] Fig. 86 includes data showing pAlu-induced RPE degeneration in a model of "dry AMD" is blocked by 2Et-d4T or 2Et-AZT.

[0093] Fig. 87 includes data showing poly IC-induced RPE degeneration in a model of "dry AMD" is blocked by Me-d4T or 2-Me-d4T.

[0094] Fig. 88 includes data showing Amyloid beta-induced RPE degeneration in a model of "dry AMD" by 3TC or K-2 (2Me-d4T).

[0095] Fig. 89 includes data showing iron-induced RPE degeneration in a model of “dry AMD” is blocked by d4T, K-1 (Me-d4T), or K-2 (2Me-d4T).

[0096] Fig. 90 includes data showing that d4T, AZT, or 3TC can cause retinal degeneration.

[0097] Fig. 91 includes data showing Kamuvudines are not toxic to the retina.

[0098] Fig. 92 includes further data showing Kamuvudines are not toxic to the retina.

[0099] Fig. 93 includes data showing that NRTIs (d4T, 3TC, or AZT) reduce mitochondrial DNA (mtDNA) while modified NRTIs (Me-d4T, 2Me-d4T, TM-3TC Me-AZT, or 2Me-AZT) do not reduce mtDNA.

[00100] Fig. 94 includes data showing that NRTIs (d4T, AZT, or 3TC) inhibit L1 retrotransposition but modified NRTIs (Me-d4T, 2Me-d4T, Me-AZT, 2Me-AZT, 3Me-3TC, 2Et-d4T, 2Et-AZT, or 3Et-3TC) do not inhibit L1 retrotransposition.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

[00101] The presently-disclosed subject matter is illustrated by specific but non-limiting examples throughout this description. The examples may include compilations of data that are representative of data gathered at various times during the course of development and experimentation related to the present invention(s). Each example is provided by way of explanation of the present disclosure and is not a limitation thereon. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the teachings of the present disclosure without departing from the scope of the disclosure. For instance, features illustrated or described as part of one embodiment can be used with another embodiment to yield a still further embodiment.

[00102] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.

[00103] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

[00104] While the terms used herein are believed to be well understood by those of ordinary skill in the art, certain definitions are set forth to facilitate explanation of the presently-disclosed subject matter.

[00105] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong.

[00106] Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

[00107] As used herein, the abbreviations for any protective groups and compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, Biochem. (1972) 11(9):1726-1732).

[00108] Following long-standing patent law convention, the terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a cell” includes a plurality of such cells, and so forth.

[00109] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently-disclosed subject matter.

[00110] As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments $\pm 20\%$, in some embodiments $\pm 10\%$, in some embodiments $\pm 5\%$, in some embodiments $\pm 1\%$, in some embodiments $\pm 0.5\%$, and in some embodiments $\pm 0.1\%$ from the specified amount, as such variations are appropriate to perform the disclosed method.

[00111] As used herein, ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[00112] As used herein, “optional” or “optionally” means that the subsequently described event or circumstance does or does not occur and that the description includes

instances where said event or circumstance occurs and instances where it does not. For example, an optionally variant portion means that the portion is variant or non-variant.

[00113] The term “physiologically functional derivative” means any pharmaceutically acceptable derivative of a compound of the present disclosure. For example, an amide or ester of a compound of formula (I) or of a compound of formula (II), which upon administration to a subject, particularly a mammal, is capable of providing, either directly or indirectly, a compound of the present disclosure of an active metabolite thereof.

[00114] The terms “treatment” or “treating” refer to the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a condition or disorder (e.g., retinal degradation). This term includes active treatment, that is, treatment directed specifically toward the improvement of a condition, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated condition. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the condition; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of symptoms or disorders of the associated condition; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

[00115] With regard to administering the compound, the term “administering” refers to any method of providing a composition and/or pharmaceutical composition thereof to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, subcutaneous administration, intravitreal administration, including via intravitreal sustained drug delivery device, intracameral (into anterior chamber) administration, suprachoroidal injection, subretinal administration, Subconjunctival injection, sub-Tenon’s administration, peribulbar administration, Transscleral drug delivery, administration via topical eye drops, and the like. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition (e.g., exposure to OP compounds). In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.

[00116] The term “effective amount” refers to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.

[00117] The terms “subject” or “subject in need thereof” refer to a target of administration, which optionally displays symptoms related to a particular disease, condition, disorder, or the like. The subject(s) of the herein disclosed methods can be human or non-human (e.g., primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, rodent, and non-mammals). The term “subject” does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. The term “subject” includes human and veterinary subjects.

[00118] As will be recognized by one of ordinary skill in the art, the terms “suppression,” “suppressing,” “suppressor,” “inhibition,” “inhibiting” or “inhibitor” do not refer to a complete elimination of angiogenesis in all cases. Rather, the skilled artisan will understand that the term “suppressing” or “inhibiting” refers to a reduction or decrease in angiogenesis. Such reduction or decrease can be determined relative to a control. In some embodiments, the reduction or decrease relative to a control can be about a 1, 2, 3, 4, 5, 6, 7,

8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease.

[00119] In some exemplary embodiments, the presently-disclosed subject matter includes methods for treating retinal damage and/or retinal degeneration. Indeed, some methods of the present disclosure comprise administering to a subject in need thereof an effective amount of a composition for treating retinal damage and/or degradation.

[00120] In some embodiments the composition comprises a nucleoside and/or a nucleoside reverse transcriptase inhibitor (NRTI). Further, in some embodiments, the composition is a pharmaceutical composition comprising a nucleoside and/or a NRTI compound as well as a pharmaceutically acceptable carrier.

[00121] As discussed herein, in some exemplary methods of the present disclosure, the administered composition is a composition comprising a nucleoside and/or NRTI. Thus, exemplary compositions are comprised of compounds including, but not limited to, stavudine (d4T), lamivudine (3TC), cordycepin, azidothymidine (AZT), abacavir (ABC), chemical derivatives thereof (e.g., methoxy-derivatives to abrogate phosphorylation), and the like. Other possible compounds include, for example, those described in U.S. Patent No. 6,514,979 to Heredia et al. Those of ordinary skill in the art will also recognize further nucleosides and/or NRTIs, as described herein, that can be used in the compositions and methods of this disclosure.

[00122] In some embodiments a method of the present disclosure comprises inhibiting activation of one or more physiological processes by Alu RNA. As disclosed herein, Alu RNA (including Alu repeat RNA in human cells and B1 and B2, Alu-like element repeat RNAs) increases are associated with cells that are associated with certain conditions of interest. For example, an Alu RNA increase is associated with the retinal pigment epithelium (RPE) cells of eyes with geographic atrophy. This increase of Alu RNA induces the death of RPE cells. Methods and compositions disclosed herein can treat RPE degradation, thereby treating conditions associated with such cell death.

[00123] In some embodiments, a method of the present disclosure comprises inhibiting the activation of at least one inflammasome. In certain embodiments, the at least one inflammasome is selected from an NLRP3 inflammasome, a 1L-1beta inflammasome, and a combination thereof. In some embodiments, the inhibiting one or more inflammasomes of a cell includes administering an inhibitor (composition) to the cell and/or to a subject, wherein

the cell is the cell of a subject. For compositions comprising an inhibitor, an inhibitor as described herein can be, for example, a polypeptide inhibitor (including an oligonucleotide inhibitor), a small molecule inhibitor, and/or an siRNA inhibitor.

[00124] Moreover, some exemplary methods of administering the present composition(s) can inhibit inflammation by LPS/ATP, inflammasome activation by LPS/ATP, inflammasome activation by Alu RNA, and/or nigericin-induced inflammasome activation. Exemplary methods can also treat retinal degradation and/or other retinal damage by reducing mitochondrial reactive oxygen species, particularly as caused by Alu RNA expression, by blocking entry via the P2X7 receptor, and/or by reducing ATP-induced cell permeability.

[00125] In some embodiments, a method of the present disclosure comprises treating retinal damage by inhibiting a particular action in a cell. In some embodiments, the cell is selected from an RPE cell, a retinal photoreceptor cell, or a choroidal cell. In some embodiments, the cell is an RPE cell. In some embodiments, the cell is the cell of a subject. In some embodiments, the cell is a cell of a subject having, suspected of having, or at risk of having a condition of interest. In some embodiments, the cell is a cell of a subject having, suspected of having, or at risk of having age-related macular degeneration. In some embodiments, the cell is a cell of a subject having, suspected of having, or at risk of having geographic atrophy. In some embodiments, the cell is a cell of a subject having, suspected of having, or at risk of having geographic atrophy and the cell is an RPE cell. In some embodiments, a subject having age-related macular degeneration can be treated using methods and compositions as disclosed herein.

[00126] Thus, as used herein with reference to a polypeptide being inhibited, “of a cell” refers to a polypeptide that is inside the cell (inside the cell membrane), on the cell (in the cell membrane, presented on the cell membrane, otherwise on the cell), or outside of a cell, but insofar as the polypeptide is outside of the cell, it is in the extracellular milieu such that one of ordinary skill in the art would recognize the polypeptide as being associated with the cell. For example, VDAC1, VDAC2, caspase-8, NFκB, or a polypeptide of an inflammasome (e.g., NLRP3, PYCARD, caspase-1) could be in the cell. For another example, NLRP3 could be in the cell or on the cell.

[00127] As described herein, the presently-disclosed subject matter further includes pharmaceutical compositions comprising the compounds described herein together with a pharmaceutically acceptable carrier.

[00128] The term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose.

[00129] Suitable formulations include aqueous and non-aqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.

[00130] The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[00131] The formulations can be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of sterile liquid carrier immediately prior to use.

[00132] For oral administration, the compositions can take the form of, for example, tablets or capsules prepared by a conventional technique with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods known in the art.

[00133] Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner.

[00134] The compositions can be formulated as eye drops. For example, the pharmaceutically acceptable carrier may comprise saline solution or other substances used to formulate eye drop, optionally with other agents. Thus, eye drop formulations permit for topical administration directly to the eye of a subject.

[00135] The compositions can also be formulated as a preparation for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt). The compounds can also be formulated in rectal compositions, creams or lotions, or transdermal patches.

[00136] The presently-disclosed subject matter further includes a kit that can include a compound or pharmaceutical composition as described herein, packaged together with a device useful for administration of the compound or composition. As will be recognized by those of ordinary skill in the art, the appropriate administration-aiding device will depend on the formulation of the compound or composition that is selected and/or the desired administration site. For example, if the formulation of the compound or composition is

appropriate for injection in a subject, the device could be a syringe. For another example, if the desired administration site is cell culture media, the device could be a sterile pipette.

[00137] Moreover, NRTIs of the present disclosure are a diverse, widely used, inexpensive class of small molecules, with extensive pharmacokinetic and safety data collected over the past several decades of human use; NRTIs are therefore ripe for drug repurposing. As such, the present disclosure provides a novel and broadly applicable basis for use of one or more NRTIs by addressing major unmet medical needs.

[00138] As briefly described above, age-related macular degeneration is a disease that affects tens of millions of people worldwide, and there is no effective treatment for AMD (Ambati and Fowler, 2012). Similarly, graft-versus host disease is the major obstacle preventing successful tissue transplant (Ferrara et al., 2009); and sterile liver inflammation is a major contributor to drug-induced liver injury and steatohepatitis, a major determinant of fibrosis and carcinogenesis (Kubes and Mehal, 2012). Thus, some methods and/or compounds of the present disclosure are intended to treat age-related macular degeneration, graft-versus host disease, and/or sterile liver inflammation by administering, in some embodiments, a compound comprising at least one NRTI, as provided in the present disclosure.

[00139] Since inflammasome inhibition by NRTIs can be achieved without phosphorylation of a particular NRTI, the use of me-d4T or other phosphorylation-incompetent nucleoside analogs, as provided herein, should avoid therapeutic-limiting toxicities associated with NRTI-triphosphate-mediated polymerase inhibition (Lewis et al., 2003). Accordingly, in some embodiments, the present disclosure is directed to methods for treating retinal disease by administering me-d4T or another phosphorylation-incompetent nucleoside analog to a subject in need thereof.

[00140] Further, in certain embodiments, the present disclosure provides methods for treating retinal damage, comprising: administering an effective amount of a compound or composition to a subject in need thereof, wherein the composition comprises a compound as disclosed herein or combinations thereof.

[00141] In some embodiments, the presently disclosed subject matter provides methods for protecting an RPE cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof, comprising at least the step of administering an effective amount of a compound or composition to a subject in need thereof, wherein the composition comprises a compound as disclosed herein or combinations thereof.


[00142] In some embodiments, the presently disclosed subject matter provides methods for conditions associated with retinal damage and/or degradation, which involve administering an effective amount of a compound or composition to a subject in need thereof, wherein the composition comprises a compound as disclosed herein or combinations thereof.

[00143] In some embodiments, the presently disclosed subject matter provides methods for treating age related macular degeneration (AMD), which involve administering an effective amount of a compound or composition to a subject in need thereof, wherein the composition comprises a compound as disclosed herein or combinations thereof. In some embodiments the AMD is wet AMD. In some embodiments the AMD is dry AMD.

[00144] As described herein, the present inventors have found that nucleoside reverse transcriptase inhibitors, which are FDA-approved for the treatment of HIV and HBV, were surprisingly found to be effective in mouse models of dry and wet age-related macular degeneration (AMD) (Fowler et al. Science 2014). However, some of the NRTIs tested by the present inventors (i.e. d4T, AZT) cause undesirable side effects in patients, which is thought to occur due to off-target effects on DNA polymerase-gamma, which leads to mitochondrial depletion. If NRTIs are to be used to treat chronic diseases such as AMD, long-term polymerase inhibition with NRTIs could hinder their clinical translation.

[00145] The present inventors designed a novel methoxy-modified version of d4T (Fowler et al. Science 2014). However, the synthesis of me-d4T was laborious (over 10 steps). Furthermore, other NRTIs such as AZT and 3TC also blocked mouse models of dry and wet AMD (Fowler et al. Science 2014; Mizutani et al. IOVS 2015, in press), although it is not known whether modified versions of these drugs are also effective in these models. Accordingly, the present-disclosed subject matter includes unique compounds useful for the indications as disclosed herein, without the drawbacks of previously-known compounds.

[00146] The presently-disclosed subject matter provides, in certain embodiments, a compound having the structure



, or a pharmaceutically acceptable salt thereof, wherein

R_1 is selected from covalent bond, H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino; in some embodiments, R_1 is selected from ethyl, butyl, propyl, 2-methylpropyl, and t-butyl; and in some embodiments R_1 is selected from covalent bond, H and $-\text{CH}_3$;

R_2 is selected from H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino; in some embodiments, R_2 is selected from ethyl, butyl, propyl, 2-methylpropyl, and t-butyl; and in some embodiments, R_2 is $-\text{N}(\text{R}_3)_2$, where each R_3 is independently selected from alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino, and in some embodiments, each R_3 is independently selected from H, CH_3 , ethyl, butyl, t-butyl, isobutyl, propyl, 2-methylpropyl, isopropyl, pentyl, and hexyl;

R_4 is selected from H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino; and in some embodiments, R_4 is selected from $-\text{CH}_3$ and ethyl;

R_5 is selected from C, CH, and S;

R_6 is selected from H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino; in some embodiments, R_6 is selected from ethyl, butyl, propyl, 2-methylpropyl, and t-butyl; and in some embodiments, R_6 is selected from $-\text{N}=\text{N}^+=\text{NH}$ and N_3 ; and

R_7 is H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino; in some embodiments, R_7 is selected from ethyl, butyl, propyl, 2-methylpropyl, and t-butyl; in some embodiments, R_7 is selected from $-\text{CH}_2-\text{O}-\text{CH}_3$, $-\text{CH}_3$, $=\text{CH}_2$, $-\text{CH}_2-\text{NH}_2$, and $-\text{CH}_2-\text{N}=\text{N}^+=\text{NH}$; and in some embodiments, R_7 is $-\text{CH}_2-\text{O}-\text{R}_8$, wherein R_8 is selected from alkyl, substituted alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino, and in some embodiments, R_8 is selected from $-\text{CH}_3$, ethyl, propyl, 2-methylpropyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl.

[00147] As used herein the term "alkyl" refers to C1-20 inclusive, linear (i.e., "straight-chain"), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, methylpropynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. "Branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. "Lower alkyl" refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C1-8 alkyl), e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. "Higher alkyl" refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, "alkyl" refers, in particular, to C1-8 straight-chain alkyls. In other embodiments, "alkyl" refers, in particular, to C1-8 branched-chain alkyls.

[00148] Alkyl groups can optionally be substituted (a "substituted alkyl") with one or more alkyl group substituents, which can be the same or different. The term "alkyl group substituent" includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxy, alkoxyl, alkylthio, arylthio, aralkyloxy, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. There can be optionally inserted along the alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl"), or aryl.

[00149] Thus, as used herein, the term "substituted alkyl" includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group are replaced with another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.

[00150] Further, as used herein, the terms alkyl and/or "substituted alkyl" include an "allyl" or an "allylic group." The terms "allylic group" or "allyl" refer to the group $\text{CH}_2\text{HC}=\text{CH}_2$ and derivatives thereof formed by substitution. Thus, the terms alkyl and/or substituted alkyl include allyl groups, such as but not limited to, allyl, methylallyl, dimethylallyl, and the like. The term "allylic position" or "allylic site" refers to the saturated carbon atom of an allylic group. Thus, a group, such as a hydroxyl group or other substituent group, attached at an allylic site can be referred to as "allylic."

[00151] "Alkylene" refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,

15, 16, 17, 18, 19, or 20 carbon atoms. The alkylene group can be straight, branched or cyclic. The alkylene group also can be optionally unsaturated and/or substituted with one or more "alkyl group substituents." There can be optionally inserted along the alkylene group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms (also referred to herein as "alkylaminoalkyl"), wherein the nitrogen substituent is alkyl as previously described. Exemplary alkylene groups include methylene ($-\text{CH}_2-$); ethylene ($-\text{CH}_2\text{CH}_2-$); propylene ($-(\text{CH}_2)_3-$); cyclohexylene ($-\text{C}_6\text{H}_{10}-$); $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$; $-\text{CH}=\text{CH}-\text{CH}_2-$; $-(\text{CH}_2)_q-\text{N}(\text{R})-(\text{CH}_2)_r-$, wherein each of q and r is independently an integer from 0 to about 20, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and R is hydrogen or lower alkyl; methylenedioxy ($-\text{O}-\text{CH}_2-\text{O}-$); and ethylenedioxy ($-\text{O}-(\text{CH}_2)_2-\text{O}-$). An alkylene group can have about 2 to about 3 carbon atoms and can further have 6-20 carbons.

[00152] As used herein, the term "acyl" refers to an organic acid group wherein the OH of the carboxyl group has been replaced with another substituent (i.e., as represented by $\text{RCO}-$, wherein R is an alkyl or an aryl group as defined herein). As such, the term "acyl" specifically includes arylacyl groups, such as an acetylfuran and a phenacyl group. Specific examples of acyl groups include acetyl and benzoyl.

[00153] "Alkoxyl" or "alkoxyalkyl" refer to an alkyl-O- group wherein alkyl is as previously described. The term "alkoxyl" as used herein can refer to C1-20 inclusive, linear, branched, or cyclic, saturated or unsaturated oxo-hydrocarbon chains, including, for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, t butoxyl, and pentoxyl.

[00154] "Acyloxyl" refers to an acyl-O- group wherein acyl is as previously described.


[00155] "Acylamino" refers to an acyl-NH- group wherein acyl is as previously described.

[00156] The term "amino" refers to the $-\text{NH}_2$ group.


[00157] A dashed line representing a bond in a cyclic ring structure indicates that the bond can be either present or absent in the ring. That is a dashed line representing a bond in a cyclic ring structure indicates that the ring structure is selected from the group consisting of a saturated ring structure, a partially saturated ring structure, and an unsaturated ring structure.

[00158] Moreover, in some embodiments, the present disclosure is directed to the compounds of, pharmaceutical compositions including compounds of, synthesis of, and/or use of one or more of the compounds disclosed hereinbelow.


[00159] In some embodiments, the presently disclosed compound has the structure of any one of Formula I-XIV, or a pharmaceutically acceptable salt thereof.




(I)
Me-AZT: 1-[(5R)-2-(methoxymethyl)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl]triazia-1,2-dien-2-ium (also referred to herein as Kamuvudine 5)




(II)
deoxy-methyl-d4T: 5-methyl-1-[2R,5R)-5-methyl-2,5-dihydrofuran-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione




(III)
methylene d4T: 5-methyl-1-[2R)-5-methylidene-2,5-dihydrofuran-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione




(IV)
2Me-d4T: 1-[(2R)-5-(methoxymethyl)-2,5-dihydrofuran-2-yl]-3,5-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (also referred to herein "Kamuvudine 2")



- (V)
deoxy-amino-d4T: 1-[(2R)-5-(aminomethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione




- (VI)
Me-3TC: 4-amino-1-[(2R,5S)-2-(methoxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one



- (VII)
deamino-Me-3TC: 1-[(2R,5S)-2-(methoxymethyl)-1,3-oxathiolan-5-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione




- (VIII)
3Me-3TC: 4-(dimethylamino)-1-[(2R,5S)-2-(methoxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one (also referred to herein as Kamuvudine 6 and TM-3TC)




(IX)

Azido-d4T: 1-[(2S,5R)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methyl]triaz-1,2-dien-2-ium




(X)

2Me-AZT: 1-[(2R,4S,5S)-4-azido-5-(methoxymethyl)oxolan-2-yl]-3,5-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (also referred to herein as Kamuvudine 4)




(XI)

O-Me N-Et d4T: 3-ethyl-1-[(2R,5S)-5-(methoxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (also referred to herein as Kamuvudine 3)




(XII)

2Et-AZT: 1-[(2R,4S,5S)-4-azido-5-(ethoxymethyl)oxolan-2-yl]-3-ethyl-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (also referred to herein as Kamuvudine 8)



(XIII)


2Et-d4T: 1-[(2R,5S)-5-(ethoxymethyl)-2,5-dihydrofuran-2-yl]-3-ethyl-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (also referred to herein as Kamuvudine 7)




(XIV)


3Et-3TC: 4-(diethylamino)-1-[2-(ethoxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one (also referred to herein as Kamuvudine 9)




[00160] In some embodiments, the presently disclosed compound has the structure of any one of the following compounds, or a pharmaceutically acceptable salt thereof:






[00161] In some embodiments, the presently disclosed compound has the structure of any one of the following compounds, or a pharmaceutically acceptable salt thereof:







[00162] In some embodiments, the presently disclosed compound has the structure of any one of the following compounds, or a pharmaceutically acceptable salt thereof:




3tc-C6-4,1,1




3tc-C6-4*,1,1




3tc-C6-4**,1,1




3tc-C6-4**,2,0




3tc-C6-5,1,0




3tc-C6-4,2,0



3tc-C6-3,3,0




3tc-C6-2,4**,0




3tc-C6-4*,2,0




3tc-C6-3*,3*,0




3tc-C6-2,4*,0




3tc-C6-2,4,0




3tc-C6-1,4,1



3tc-C6-1,4*,1




3tc-C6-1,2,3




3tc-C6-1,2,3*




3tc-C6-1,4**,1




3tc-C6-3,1,2




3tc-C6-2,1,3




3tc-C6-2,1,3*




3tc-C7-1,3*,3*




3tc-C7-1,3,3




3tc-C7-1,2,4




3tc-C7-1,2,4*




3tc-C7-1,2,4**




3tc-C7-2,2,3*




3tc-C7-2,2,3




3tc-C7-3,1,3




3tc-C7-3,2,2




3tc-C7-4,0,3




3tc-C7-4**,0,3




3tc-C7-3*,1,3*




3tc-C7-3*,2,2




3tc-C7-4**,1,2





3tc-C7-4,1,2




3tc-C8-3',2,3




3tc-C8-2,3'3'




3tc-C8-2,2,4




3tc-C8-4,2,2



3tc-C8-2,3,3



3tc-C8-3',2,3'



3tc-C9-3*,3*,3*

or

[00163] Further, the present disclosure provides uses of the compounds disclosed herein, or any combination thereof, in the preparation or manufacture of a pharmaceutical composition, such as a drug and/or medicine, especially a composition for the treatment of retinal damage and/or retinal degeneration in a mammal. In some embodiments, the present disclosure provides a pharmaceutical composition comprising the compounds as disclosed

herein, any salt, particularly any pharmaceutically acceptable salt, any solvate, and/or any physiological derivative thereof, together with a pharmaceutically acceptable carrier.

[00164] In certain embodiments, the methods and compositions of the present disclosure inhibit graft-versus-host disease, chronic pain, proliferative vitreoretinopathy, glaucoma, rheumatoid arthritis, multiple sclerosis, bipolar disorder, major depressive disorder, renal fibrosis, nephritis, pulmonary fibrosis, Huntington's disease, osteoporosis, chronic lymphocytic leukemia, anxiety disorders, pulmonary tuberculosis, osteoporosis in post-menopausal women and fracture patients, systemic lupus erythematosus, discoid lupus erythematosus, chronic inflammatory and neuropathic pain, autosomal dominant polycystic kidney disease, spinal cord injury, Alzheimer's disease, neuropathic pain, hypertension, varicose veins, type I diabetes, type II diabetes, gout, autoimmune hepatitis, graft vascular injury, atherosclerosis, thrombosis, metabolic syndrome, salivary gland inflammation, traumatic brain injury, ischemic heart disease, ischemic stroke, Parkinson's disease, melanoma, neuroblastoma, prostate, breast, skin, and thyroid cancers, tubular early gastric cancer, neuroendocrine cancer, mucoid colon cancer, colon cancer, high-grade urothelial carcinoma, kidney clear cell carcinoma, undifferentiated ovary carcinoma, papillary intracystic breast carcinoma, gram negative sepsis, infectious *Pseudomonas aeruginosa*, *Vibrio cholera*, *Legionella* spp., *Francisella* spp., and *Leishmania* spp. *Chlamydia* spp., cryopyrinopathies; keratitis, acne vulgaris, Crohn's disease, ulcerative colitis, irritable bowel syndrome, insulin resistance, obesity, hemolytic-uremic syndrome, polyoma virus infection, immune complex renal disease, acute tubular injury, lupus nephritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease, chronic infantile neurologic cutaneous and articular autoinflammatory diseases, renal ischemia-perfusion injury, glomerulonephritis, cryoglobulinemia, systemic vasculitides, IgA nephropathy, malaria, helminth parasites, septic shock, allergic asthma, hay fever, chronic obstructive pulmonary disease, drug-induced lung inflammation, contact dermatitis, leprosy, *Burkholderia cenocepacia* infection, respiratory syncytial virus infection, psoriasis, scleroderma, reactive arthritis, cystic fibrosis, syphilis, Sjögren's syndrome, inflammatory joint disease, non-alcoholic fatty liver disease, cardiac surgery (peri-/post-operative inflammation), acute and chronic organ transplant rejection, acute and chronic bone marrow transplant rejection, tumor angiogenesis, amyotrophic lateral sclerosis, autism spectrum disorder (e.g., through Kamuvudine blockade of P2X7, as shown in mouse models of autism), and/or any combination thereof.

[00165] Moreover, in some embodiments, the present disclosure provides that non-canonical NRTI function, independent of chain termination, prevents P2X7-dependent blindness, graft-versus-host disease and/or sterile inflammation. Accordingly, the present disclosure is directed, in certain embodiments, to methods of preventing P2X7-dependent blindness, graft-versus-host disease and/or inflammation in a subject by administering an effective amount of at least one NRTI, as described herein, to subject in need thereof.

[00166] Further, in certain embodiments, the methods and compositions of the present disclosure inhibit (i) inflammasome activation by Alu RNA associated with a cell; (ii) inflammation by LPS/ATP, (iii) inflammasome activation by LPS/ATP, (iv) nigericin-induced inflammasome activation, and/or combinations thereof. And in some embodiments, the inflammasome is selected from the group consisting of a NLRP3 inflammasome and/or a IL-1beta inflammasome. Additionally, some embodiments of the methods of the present disclosure may include, for example, the steps of (i) blocking entry via a P2X7 receptor associated with a cell; (ii) reducing mitochondrial reactive oxygen species caused by Alu RNA expression; and/or (iii) reducing ATP-induced cell permeability of a cell. And a cell contemplated in the present disclosure may include, for example, an RPE cell, a retinal photoreceptor cell, a choroidal cell, or any combination thereof.

[00167] Further, NRTIs are mainstay therapeutics for HIV, and they block retrovirus replication. *Alu* RNA, an endogenous retroelement that also requires reverse transcriptase (RT) for its life cycle, activates the NLRP3 inflammasome to cause cell death of the retinal pigment epithelium in geographic atrophy, which is the untreatable form of age-related macular degeneration that blinds millions of individuals. Moreover, the inventors of the present disclosure have found that NRTIs, as a class, are novel inhibitors of the NLRP3 inflammasome. And, surprisingly, this effect is independent of reverse transcriptase inhibition.

[00168] The details of one or more embodiments of the presently-disclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and other embodiments, will be evident to those of ordinary skill in the art after a study of the information provided in this document. The information provided in this document, and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood therefrom. In case of conflict, the specification of this document, including definitions, will control.

[00169] The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples. The following examples may include compilations of data that are representative of data gathered at various times during the course of development and experimentation related to the present invention.

EXAMPLES

[00170] Example 1

[00171] The inventors of the present disclosure have found that the NRTIs d4T, AZT, ABC, and 3TC block Caspase 1 activation by *Alu* RNA, as does 5'-methoxy-d4T, which does not inhibit reverse transcriptase. Further, the present inventors have found that AZT is not phosphorylated in thymidine kinase-deficient cells but still blocks LPS/ATP-induced interleukin-1 beta secretion; that NRTIs block P2X7-dependent YOPRO-1 dye uptake and mouse models of geographic atrophy, graft-versus-host disease, and sterile liver inflammation; and that NRTIs are novel inhibitors of the NLRP3 inflammasome independent of canonical reverse transcriptase inhibition. Accordingly, NRTIs are ripe for drug repurposing in a variety of P2X7-driven diseases.

[00172] NRTIs were first discovered to be anti-viral compounds in 1974 (Ostertag et al., 1974), and are widely used to treat human immunodeficiency virus (HIV). The canonical mechanism of action of NRTIs is via chain termination of DNA synthesis from a viral RNA template, thereby interfering with the viral life cycle of reverse transcriptase-dependent viruses.

[00173] Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly worldwide (Ambati et al., 2003; Ambati and Fowler, 2012). In the more prevalent and untreatable dry form of AMD, overabundance of non-coding *Alu* RNAs causes blindness by inducing cell death of the retinal pigment epithelium (Dridi et al., 2012; Kaneko et al., 2011; Tarallo et al., 2012). *Alu* sequences are non-coding retrotransposons that, like HIV, rely on reverse transcriptase for their life cycle (Batzer and Deininger, 2002; Dewannieux et al., 2003).

[00174] *Alu* RNA mediates RPE cell death via activation of Caspase 1 and the NLRP3 inflammasome (Tarallo et al., 2012). The present disclosure provides that a reverse transcriptase inhibitor, such as stavudine (d4T; 2'3' dideoxythymidine; Zerit, Bristol-Myers Squibb), which is FDA-approved for the treatment of HIV, prevents Caspase 1 cleavage to its active 20 kDa form (Hentze et al., 2003; Yamin et al., 1996) in primary human (FIG. 34) and mouse RPE cells (FIG. 44) without reducing *Alu* RNA levels (FIG. 45). Further, the present

disclosure shows that d4T also blocks phosphorylation of IRAK4, a kinase downstream of the MyD88 adaptor that mediates *Alu*-induced RPE cell death (Tarallo et al., 2012), in human and mouse RPE cells (FIG. 34 and FIG. 44). The inventors of the present disclosure have also found that other NRTIs, including the anti-HIV drugs azidothymidine (AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV Healthcare), lamivudine (3TC; 2'3' dideoxycytidine; Zeffix, GlaxoSmithKline) and abacavir (ABC; a di-deoxyguanosine analog; Ziagen, ViiV Healthcare), also block Caspase-1 cleavage induced by *Alu* RNA (FIG. 35).

[00175] Additionally, the present disclosure provides that d4T and AZT prevent RPE degeneration in the *Alu* RNA-induced mouse model of dry AMD. (Kaneko et al., 2011; Tarallo et al., 2012) Moreover, it has been found that mice receiving daily oral administration of d4T blocked RPE degeneration after sub-retinal injection of a plasmid expressing *Alu* RNA (FIG. 36), as did intraperitoneal administration of AZT (FIG. 37).

[00176] In order to test whether reverse transcriptase inhibition was required for inflammasome blockade by d4T, a 5' O-methyl-modified version of d4T (5'-OCH₃-d4T; me-d4T) was synthesized (FIG. 20; FIG. 25, FIG. 36, FIG. 27, FIG. 28). Accordingly, in some embodiments, the present disclosure is directed to methods for synthesizing a 5' O-methyl-modified version of d4T as provided herein.

[00177] Only the triphosphate version of nucleoside analogs inhibits reverse transcriptase; the methyl modification at the 5' position prevents phosphorylation and thus formation of nucleoside triphosphate (Nykanen et al., 2001). Accordingly, like d4T, me-d4T also blocks Caspase-1 activation in human RPE cells (FIG. 21).

[00178] The present inventors have confirmed that me-d4T does not inhibit reverse transcriptase; and, in contrast to unmodified d4T, me-d4T does not block lentivirus replication (FIG. 22). Also, the triphosphate metabolite of di-deoxy nucleoside analogs caused depletion of mitochondrial DNA; and consistent with the idea that me-d4T is not phosphorylated, it has been found that d4T, but not me-d4T reduces mtDNA levels. (FIG. 23). Me-d4T also prevents *Alu*-induced RPE degeneration in mice (FIG. 24). These data indicate that d4T can block Caspase-1 activation and RPE degeneration independent of reverse transcriptase inhibition.

[00179] Further, the present inventors also tested whether NRTIs blocked inflammasome activation by LPS/ATP, which is not known to signal via reverse transcriptase (Mariathasan et al., 2004; Mariathasan et al., 2006; Martinon et al., 2002). It was found that d4T inhibited LPS/ATP-induced Caspase-1 maturation in primary mouse bone marrow-derived macrophages (FIG. 38) as detected by Western blot.

[00180] Caspase-1 directly processes interleukin 1 beta (IL-1 beta) upon LPS/ATP stimulation; d4T also blocks secretion of mature IL-1 beta in these cells (FIG. 39). To determine whether LPS/ATP-induced inflammasome activation can be inhibited without RT inhibition, the present inventors utilized thymidine kinase-deficient (Raji/TK⁻) and -expressing (Raji/TK⁺) cells (Balzarini et al., 1989). After addition of AZT, TK⁺, but not TK⁻ cells, the present inventors produced AZT-triphosphate (AZT-TP), the AZT metabolite required for RT inhibition (FIG. 40; FIG. 46, FIG. 47, FIG. 48, FIG. 49, FIG. 50). Even though AZT was not phosphorylated in TK⁻ cells, AZT still inhibited LPS/ATP-induced interleukin-1 beta maturation (FIG. 41), indicating that AZT did not inhibit interleukin-1 beta maturation via reverse transcriptase inhibition.

[00181] *Alu* RNA (Kerur et al., 2013) and LPS/ATP (Qu et al., 2011) activate the inflammasome via the ATP receptor P2X7. The present inventors therefore hypothesized that d4T blocks P2X7 or some P2X7-dependent pathway. First, testing was conducted to determine whether d4T acts upstream of P2X7 by modulating ATP levels; however, d4T does not block release of ATP to cell culture media induced by *Alu* RNA (FIG. 42).

[00182] Next, testing was conducted to determine whether d4T directly antagonizes P2X7 function: upon ATP binding, cell-surface P2X7 forms non-selective cation channels that mediate inflammasome activation (Kahlenberg and Dubyak, 2004; Petrilli et al., 2007). However, d4T did not significantly modulate P2X7 cation channel function as monitored by patch clamp analysis of HEK293 cells expressing either the mouse or rat P2X7 receptor (Humphreys et al., 2000).

[00183] Finally, P2X7 activation is associated with the formation of a large pore that is permeable to molecules of up to ~ 1000 Da (Adinolfi et al., 2005; Cheewatrakoolpong et al., 2005; Surprenant et al., 1996). It was found that d4T, and also AZT and 3TC, inhibited P2X7-dependent uptake of the fluorescent dye YO-PRO1 (M.W. Da) in human P2X7-overexpressing HEK293 stable cell line (FIG. 43) after addition of the selective P2X7 agonist bzATP.

[00184] Consistent with the idea that NRTIs block *Alu*-induced P2X7-mediated inflammasome activation via a mechanism involving dye uptake, *Alu* RNA-induced Caspase-1 activation was inhibited by a small peptide that blocks P2X7-mediated dye uptake and LPS/ATP-induced inflammasome activation, but not cation flux (Pelegrin and Surprenant, 2006) (FIG. 51). On the other hand, *Alu*-induced Caspase-1 activation was not inhibited by calmidazolium, which selectively blocks P2X7-mediated cation flux but not dye uptake (FIG. 52).

[00185] Furthermore, the intracellular C-terminus of P2X7 governs P2X7-associated dye uptake, and a version of d4T that is not cell permeable (Agarwal et al., 2011) does not block caspase-1 activation by *Alu* RNA (FIG. 53, FIG. 32). Consistent with antagonism at or downstream of P2X7, but upstream of mitochondrial dysfunction, d4T blocks mitochondrial ROS (mtROS) production, which are produced upon LPS/ATP stimulation (Adinolfi et al., 2005; Cruz et al., 2007; Garcia-Marcos et al., 2005; Nakahira et al., 2011) and *Alu* overexpression (Tarallo et al., 2012) was measured by MitoSOx assay (FIG. 54). Finally, d4T does not prevent P2X7-independent interleukin 1-beta secretion in PMA-primed THP-1 cells treated with crystalline monosodium urate (FIG. 11) (Martinon et al., 2006; Riteau et al., 2012).

[00186] To explore the potential therapeutic relevance of NRTIs beyond the *Alu*-induced model of geographic atrophy (GA), it was hypothesized that if NRTIs function as generic inflammasome inhibitors, then they might be broadly useful in other animal models of disease that are also driven by P2X7. In the NLRP3 inflammasome- and P2X7-driven graft-versus-host disease model (Jankovic et al., 2013; Wilhelm et al., 2010), treatment of mice receiving allogeneic bone marrow and T cells with d4T showed improved survival compared to saline treated controls (30-70% vs. 0%). Furthermore, in the NLRP3- and P2X7-driven model of sterile inflammation (McDonald et al., 2010), d4T reduced neutrophil migration to the focus of liver injury.

[00187] Interestingly, it has been shown that P2X7-dependent pore function alone can influence phenotype (Sorge et al., 2012). However, at present, there are not any FDA-approved drugs that selectively target downstream P2X7 signaling and not ion channel activation. Therefore, NRTIs could be valuable both clinically and experimentally in the selective targeting of P2X7 function.

[00188] A role for P2X7 in regulating HIV replication was recently proposed (Hazleton et al., 2012), and HIV patients have increased plasma IL-18 levels (Ahmad et al., 2002; Iannello et al., 2010), which decrease after treatment with NRTI-containing highly active anti-retroviral therapy (Stylianou et al., 2003). Notably, reduction of plasma IL-18 levels by NRTI treatment of HIV-1 infected patients did not significantly associate with viral load or CD4+ T-cell counts (David et al., 2000), indicating that NRTIs can dampen IL-18 levels before inhibition of viral replication occurs. IL-18 maturation requires pro-IL18 cleavage by active Caspase 1, which typically also requires P2X7 activation. Thus, the methods and experiments of the present disclosure are consistent with the idea that NRTIs

can modulate HIV-induced cytokine expression independent of reverse transcriptase inhibition.

[00189] In some embodiments, d4T prevents RPE degeneration induced by Alu RNA in wild type mice. As shown in FIG. 1, sub-retinal Alu RNA administration to mice causes RPE degeneration in a mouse model of age-related macular degeneration. Indeed, as shown, d4T co-delivered to the vitreous humor of wild type mice prevents Alu RNA-induced RPE cell death in a dose-dependent manner at one week after delivery. The top row of FIG. 1 provides an ocular fundus photograph of mice receiving control PBS, or Alu RNA treatment, with or without increasing amounts of d4T (left to right). Arrows denote depigmented regions of RPE cell death, which resolve at highest dose of d4T. The bottom row of FIG. 1 shows an RPE flat mount, stained for intercellular junctions (ZO-1) in red that are disrupted upon Alu RNA administration, but restored to healthy RPE morphology/intercellular junctions at highest dose of d4T.

[00190] Meanwhile, in certain embodiments, d4T protects against cytotoxicity induced by plasmid expressing Alu RNA *in vitro*. FIG. 2 shows that human (HeLa) cells treated with an enforced expression plasmid for Alu RNA (pAluA) for denoted amounts of time exhibited profoundly reduced viability compared to a null plasmid (pUC19), as monitored by MTS proliferation assay, and that d4T co-administration prevented cell death induced by Alu overexpression.

[00191] In some exemplary embodiments, d4T does not rescue cytotoxicity via reduction in Alu RNA levels. As presented in FIG. 3, primary human RPE cells treated with antisense oligonucleotides targeting DICER1 (Dcr as) (lane 3 (third lane from left)) show increased Alu RNA levels in the nuclear compartment compared to control antisense oligonucleotides (Ctr as) (lane 1 (leftmost)), monitored by Northern blotting using an Alu-specific probe. Meanwhile, co-administration of d4T (lanes 2 and 4) does not reduce Alu RNA levels. FIG. 3 shows u6 (bottom row) as a loading control for nuclear fraction.

[00192] Moreover, in some embodiments, d4T does not reduce Alu RNA levels. For example, primary human RPE cells may be transfected with Alu RNA, with or without d4T. (FIG. 4) And, as presented in FIG. 4, co-administration of d4T does not change Alu RNA levels at 1, 4, or 24 hours after transfection in the nuclear fraction, as detected by Northern blotting using an Alu-specific probe. U6 (bottom row) is shown as loading control for nuclear fraction in FIG. 4.

[00193] The present disclosure further provides that, in some embodiments, d4T inhibits inflammasome activation by Alu RNA. Indeed, Alu RNA causes NLRP3

inflammasome activation, which is marked by processing of the enzyme Caspase 1, and FIG. 5 provides a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (Top, Lane 2, lower band), which is blocked by co-treatment with d4T (100 μ M; Lane 3). The bottom row in FIG. 5 is a vinculin loading control.

[00194] In certain embodiments, 3TC inhibits inflammasome activation by Alu RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the enzyme Caspase 1. FIG. 6 is a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (top, lane 2, lower band), which is blocked with co-treatment with 3TC (20-100 μ M; lane 3). On the bottom, the loading control, vinculin, is visible.

[00195] Next, FIG. 7 provides evidence of AZT, cordycepin, and abacavir inhibition of inflammasome activation by Alu RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the enzyme Caspase 1. FIG. 7 is a Western blot showing that Alu RNA causes Caspase-1 maturation in primary human RPE cells at 24 hours after Alu administration (top, lane 2, lower band), which is blocked with co-treatment with azidothymidine (AZT), cordycepin, and abacavir (ABC) (50-100 μ M; Lanes 3-8). Again, the loading control vinculin is shown on the bottom.

[00196] In certain embodiments, the present disclosure provides that d4T inhibits inflammasome activation by LPS/ATP. As such, FIG. 8 provides a gel showing that primary human RPE cells treated with LPS/ATP, a classic inflammasome activator, exhibit increased Casp-1 activation, and phosphorylation of IRAK4, which is also a marker of inflammasome signaling via the cell surface receptor adaptor protein MyD88. Moreover, as shown in FIG. 8, d4T (25/100 μ M) blocks Casp-1 activation and IRAK4 phosphorylation induced by LPS/ATP. The loading control in FIG. 8 is vinculin. Furthermore, as shown, LPS and ATP activate the NLRP3 inflammasome only in combination, thus treatment with one or the other alone is useful as a control for this experiment.

[00197] The present disclosure further provides that, in exemplary embodiments, d4T and other NRTIs reduce inflammasome activation by LPS/ATP. As presented in FIG. 9, d4T, 3TC, and cordycepin (at 100 μ M), all di-deoxy nucleoside reverse transcriptase inhibitors, inhibit Caspase-1 activation (active p20 band, top) and IL-18 maturation (bottom) induced by LPS/ATP. To produce FIG. 9, cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/ATP treatment of mouse bone marrow-derived macrophages and run on Western blotting probing with antibodies for Caspase-1 and IL-18.

[00198] In some embodiments of the present disclosure, d4T inhibits nigericin-induced inflammasome activation. Per FIG. 10, d4T (100, 250 uM) inhibits IL-1 beta maturation (top, 18 and 22 kDa forms) and Caspase-1 activation (active p20 band, bottom) induced by nigericin. Cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/nigericin treatment of mouse bone marrow-derived macrophages, and run on Western blotting probing with antibodies for IL-1 beta and Caspase-1. FIG. 10 shows the results of these efforts.

[00199] Additionally, in some embodiments, d4T does not inhibit IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. Human THP-1 monocytes were differentiated into macrophages with PMA. As shown in FIG. 11, treatment with monosodium urate (MSU), a known inflammasome activator, increased IL-1 beta secretion compared to non-treated cells, whereas d4T co-administration at a range of doses (25-1000 uM) did not significantly affect IL-1 beta secretion. Further, d4T does not block MSU-induced IL-1 beta secretion as determined by ELISA (n=3-4).

[00200] In certain embodiments, d4T and other nucleoside reverse transcriptase inhibitors do not inhibit IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. To illustrate this, human THP-1 monocytes were differentiated into macrophages with PMA. Treatment with MSU increased IL-1 beta secretion compared to non-treated cells. (FIG. 12) Meanwhile d4T, 3TC, or cordycepin (all are di-deoxy nucleotide analogs) co-administration at a range of doses (25-1000 uM) did not significantly affect IL-1 beta secretion, as shown in FIG. 12.

[00201] Next, in some embodiments, d4T reduces NLRP3 priming induced by Alu RNA. Indeed, as provided in the bar graph of FIG. 13, Alu RNA transfection increases NLRP3 mRNA levels in primary human RPE cells at 16 hours, an event termed "priming" (Y-axis) compared to mock (transfection reagent alone). This effect is blunted by co-administration of d4T (100 uM) and normalized to 18S RNA control.

[00202] Furthermore, in exemplary embodiments of the present disclosure, d4T reduces IL-1 beta priming induced by Alu RNA. FIG. 14 illustrates that Alu RNA transfection increases IL-1 beta mRNA levels in primary human RPE cells at 24 hours, an event termed "priming", (Y-axis) compared to mock (transfection reagent alone). This effect is blunted by co-administration of d4T (100 uM) and normalized to 18S RNA control.

[00203] Meanwhile, in some embodiments, d4T reduces mitochondrial ROS caused by Alu expression. FIG. 15 demonstrates that enforced expression of Alu (pAluA) causes increased mitochondrial reactive oxygen species (mtROS), as detected by MitoSox assay. In

order to produce FIG. 15, primary human RPE cells were incubated with Alu expressing plasmid or control plasmid (pUC19) with or without d4T. After 15 hours cells were co-stained for mtROS (red) and for cell count, nuclei (blue; Hoechst DNA stain). Cells in the pAluA group exhibited greater mtROS staining (red) compared to pUC19 control, an effect that is reduced in pAluA + d4T treated cells.

[00204] And in further embodiments, d4T does not inhibit ATP release induced by Alu RNA. (FIG. 16) Primary human RPE cells treated with Alu RNA for the times indicated release ATP. To provide FIG. 16, cell culture supernatant was collected from mock or Alu RNA treated cells, with or without d4T. ATP was detected using an ATP-dependent luciferase assay. And, notably, d4T did not affect ATP release.

[00205] In certain embodiments, d4T reduces ATP-induced cell permeability to Yo-Pro1 (P2X7 receptor assay), as shown in FIG. 17. To prepare FIG. 17, THP-1 cells differentiated into macrophages by PMA allowed entry of the large fluorescent dye Yo-Pro 1, in an assay for P2X7 receptor activity. It was observed that d4T dose-dependently reduced Yo-Pro entry induced by ATP, determined by an area-scan fluorescent measurement in a 96 well microplate reader. Indeed, FIG. 17 provides the results of the fluorescence measurement in relative fluorescence units (RFU, y-axis).

[00206] Furthermore, it has been shown that d4T reduces extracellular potassium levels that increase after Alu RNA transfection. (FIG. 18) Indeed, cell culture potassium levels increase in primary human RPE cells treated with Alu RNA for 6 hours, an effect that is reduced by d4T co-administration. For FIG. 18, potassium levels were determined in cell culture supernatants spectrophotometrically using a potassium-dependent pyruvate kinase assay.

[00207] Next, in some embodiments, d4T blocks bzATP-induced cell permeability to Yo-Pro1 (P2X7 receptor assay), as shown in FIG. 19. d4T blocked YO-PRO-1 iodide entry in HEK293 cells stably expressing the human P2X7 receptor stimulated with the P2X7-selective agonist bzATP. Cells were pre-incubated with d4T for 30 minutes prior to addition of bzATP/YO-PRO, and fluorescence at 485/515 nm measured at t=30 minutes.

[00208] Moreover, d4T blocks *Alu*-induced RPE degeneration and Caspase-1 activation independent of reverse transcriptase inhibition.

[00209] In some embodiments, the present disclosure is directed to a compound having the structure(s) provided in FIG. 20. FIG. 20 includes a chemical structure of methoxy-d4T (me-d4T) and of d4T. As shown in FIG. 20, a single substitution of the ribose 5' hydroxyl group with a methoxy group (circled) has been designed by the inventors of the present

disclosure to prevent d4T phosphorylation. Accordingly, in some embodiments, the present disclosure is directed to a compound comprising a single substitution of a ribose 5' hydroxyl group with a methoxy group. And, in some embodiments, the present disclosure provides compounds comprising a methoxy group in place of a ribose 5' hydroxyl group for preventing phosphorylation, such as d4T phosphorylation.

[00210] The present disclosure further provides the results of additional experiments in FIG. 21-FIG. 23. Indeed, FIG. 21 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA $\pm$ me-d4T; FIG. 22 shows cells, wherein unmodified d4T, but not me-d4T, blocks replication of a GFP-expressing lentivirus in HeLa cells; and FIG. 23 provides a graph illustrating that unmodified d4T, but not me-d4T, reduces mtDNA levels (normalized to chromosomal DNA exon-intron junction sequence) in primary mouse RPE cells as determined by real-time quantitative PCR. $n=4$, $*p < 0.05$ by Student's *t*-test.

[00211] In some embodiments, it has been shown that Me-d4T (intraperitoneal injection) prevents *Alu*-induced RPE degeneration in mice. FIG. 24, top row, provides flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Degeneration is outlined in FIG. 24 by blue arrowheads. Representative images of $n = 4$ are shown.

[00212] Meanwhile, FIG. 25 provides a schematic overview of me-d4T synthesis, and FIG. 26 is an HPLC chromatogram of me-d4T (peak # 6) final product, $>97\%$ purity. And FIG. 27 is a ^1H NMR spectroscopy of me-d4T final product, wherein the chemical shifts are consistent with the structure, and FIG. 28 provides the results of liquid chromatography/mass spectrometry of me-d4T final product, m/z ratio consistent with the structure.

[00213] FIG. 29, FIG. 30 and FIG. 31 provide for methoxy variants of nucleoside analogs. Specifically, FIG. 29 shows the chemical structure of 3TC (2'3' dideoxycytidine); FIG. 30 provides the chemical structure of AZT (3'-azido-2',3'-dideoxythymidine); and FIG. 31 shows the chemical structure of ABC (cyclopropylaminopurinylcyclopentene). In each of FIGS. 29-31, the methoxy variation (O-methyl group) of nucleoside analog is circled. Further, FIG. 32 shows a cell permeant variant of d4T (IC-d4T), where "n" group is equal to 11. Derivatives include cell permeant variants of 3TC, AZT, ABC, where the nucleobase group (circled) may be replaced, in various embodiments, by 3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, ABC (FIG. 29-31), or derivatives thereof.

[00214] Meanwhile, FIG. 33 provides the chemical structure of an exemplary NRTI according to the present disclosure.

[00215] In certain embodiments, the present disclosure provides that NRTIs block *Alu*-induced RPE degeneration and/or Caspase-1 activation. For example, FIG. 34 shows a Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in primary human RPE cells transfected with *Alu* RNA $\pm$ d4T. FIG. 35 is a Western blot of Caspase-1 activation in human RPE cells transfected with *Alu* RNA $\pm$ NRTIs (3TC, AZT, ABC). FIG. 36 shows that pAlu causes RPE degeneration, which is prevented by oral administration of d4T, and FIG. 37 shows that pAlu causes RPE degeneration, which is prevented by intraperitoneal administration of AZT. FIG. 36 and FIG. 37 include fundus photographs: top row; flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Degeneration is outlined by blue arrowheads. Scale bars, 50 μ m.

[00216] FIGS. 38-41 illustrate that NRTIs block LPS/ATP-induced inflammasome activation. FIGS. 38 and 39 show that d4T blocked Caspase-1 (FIG. 38) and IL-1 beta (FIG. 39) activation in LPS/ATP treated primary mouse bone marrow-derived macrophages as determined by western blot of cell culture media and lysate. Moreover, FIG. 40 presents chromatograms showing that Raji TK⁺ cells, but not Raji TK⁻ cells, phosphorylate AZT to AZT-triphosphate (AZT-TP) as determined by liquid chromatography-mass spectrometry (LC-MS). And FIG. 41 shows that AZT blocks IL-1 beta activation by LPS/ATP in both Raji TK⁻ and TK⁺ cells as determined by western blot of cell lysates. Representative images of n = 3-4 experiments are provided in each of FIGS. 38-41.

[00217] In some embodiments, the present disclosure provides that NRTIs selectively block P2X7 pore function and P2X7-driven models of graft rejection and sterile liver inflammation, as shown in FIGS. 42-43. FIG. 42 is a bar graph illustrating that d4T does not block *Alu*-induced ATP release from primary human RPE cells (n=4). Meanwhile, FIG. 43 is a graph illustration showing that NRTIs selectively block P2X7 pore function and P2X7-driven models of graft rejection and sterile liver inflammation, providing a graph of the fluorescence (% of bzATP) over time (minutes).

[00218] And in certain exemplary embodiments, the present disclosure provides that d4T blocks Caspase-1 activation without reducing *Alu* RNA levels. Accordingly, FIG. 44 provides a Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in primary mouse RPE cells transfected with *Alu* RNA $\pm$ d4T. And FIG. 45 presents a Northern blot of biotin-UTP-labeled *Alu* RNA-transfected primary human RPE cells. Notably, in FIG. 45, d4T did not reduce *Alu* RNA levels (normalized to u6 RNA).

[00219] Next, FIGS. 46-47 provide LC-MS/MS spectra of AZT-triphosphate (AZT-TP, target compound; FIG. 46) and AZU-triphosphate (AZU-TP, internal standard; FIG. 47).

And FIGS. 48-49 show the chromatographic separation of Raji TK⁺ cells spiked with AZT-TP (FIG. 48) and AZU-TP (FIG. 49) with MS spectra (insets) to confirm identity of designated peaks.

[00220] FIG. 50 is a standard curve of AZT-TP standards (black circle). Raji TK⁺ samples treated with AZT produced AZT-TP (white triangles), whereas AZT-TP was not detectable in Raji TK⁺ cells treated with AZT. FIG. 50 is representative of two experiments.

[00221] FIGS. 51-54 show that, in some exemplary embodiments, P2X7-dependent pore function mediates *Alu*-induced Caspase-1 activation. Indeed, FIG. 51 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with short peptide (Panx1¹⁰), which blocks P2X7 pore function but not cation flux (vs. scrambled peptide: Scr Panx1¹⁰); FIG. 52 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with calmidazolium (FIG. 32 provides the chemical structure of IC- and EC-d4T used), which blocks P2X7 cation flux but not pore function; and FIG. 53 is a Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA, with cell permeable (IC), cell-impermeable (EC), or unmodified (no tag) d4T. Furthermore, FIG. 54 shows that d4T prevents p*Alu*-induced mitochondrial ROS generation in primary human RPE cells. In FIG. 54, mitochondrial reactive oxygen species (ROS) were visualized with MitoSox (Red) and cell nuclei with Hoechst (Blue).

[00222] Caspase-1 activation (p20 subunit) in primary human retinal pigment epithelium (RPE) cells in the presence of iron (III) ammonium citrate was studied. The addition of TM-3TC (Structure 8) (25 μ M) blocked iron-induced Caspase-1 activation, as reflected in the western blot set forth in Fig. 55. The addition of 2me-d4T (Structure 4) (25 μ M) blocked iron-induced Caspase-1 activation, as reflected in the western blot set forth in Fig. 57.

[00223] Caspase-1 activation (p10 subunit) in primary human RPE cells in the presence of iron (III) ammonium citrate was studied. The addition of d4T-ene (Structure 3) (25 μ M) blocked iron-induced Caspase-1 activation, as reflected in the western blot set forth in Fig. 56.

[00224] Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with *Alu* RNA. The addition of d4T-ene (Structure 3) and TM-3TC (Structure 8) (25 and 100 μ M) blocked *Alu*-induced Caspase-1 activation, as reflected in the western blot set forth in Fig. 58.

[00225] The relative quantity of mtDNA in primary human RPE cells treated with NRTIs or derivatives (50 μ m for each) was studied using vehicle treatment (DMSO) ("No Tx") as a control. DNA was collected after four days in cell culture with exposure to drug. Quantitative polymerase chain reaction was performed for mtDNA and normalized to genomic DNA sequence. As reflected in Fig. 59, modified versions of d4T that are not phosphorylated (e.g. me-d4T (Fig. 20), 2 me-d4T (Structure 4)) do not exhibit mtDNA depletion compared to parental NRTI (d4T). TM-3TC is structure 8. As reflected in FIG. 60, modified versions of AZT that are not phosphorylated (me-AZT (Structure 1), N-Me-Me-AZT (Structure 10) do not exhibit mtDNA depletion compared to parental compound (AZT).

[00226] Mouse studies were conducted to study treatment with NRTIs or derivatives. Mice receiving subretinal control empty-vector plasmid (pNull), or Alu RNA-expressing plasmid (pAlu), were treated with twice daily intraperitoneal modified NRTIs (me-AZT (Structure 1), N-me-me-AZT (Structure 10), or 2 me-d4T (Structure 4); 25 mg/kg/administration) or control vehicle. The top row of Fig. 61 displays ocular fundus photographs of the mice. The bottom row of Fig. 61 displays RPE flat mounts, stained for intercellular junctions (ZO-1) in red that are disrupted upon Alu RNA expression but that are restored to healthy RPE morphology/intercellular junctions with modified NRTI treatment.

[00227] A schematic overview of the synthesis of Formula I (structure C in Scheme 1), Formula IV (structure B), Formula VIII (structure E), Formula X (structure D), and methoxy-d4T (structure A; also Fig. 20) is set forth in Fig. 62. The general synthesis procedure is as follows: To a suspension of nucleotide (1.5 mmole) in dry THF (5 mL) was added NaH (15 mmole) and the mixture was stirred for 10 minutes at room temperature under nitrogen. Methyl Iodide (15 mmole) was added in one portion to the mixture and stirred for 1-3h. The reaction was checked for completion by TLC and quenched by drop-wise addition of methanol. The mixture was neutralized with acetic acid and evaporated. The residue was suspended in dichloromethane and washed with aqueous NaHSO₃ solution, dried over MgSO₄ and evaporated the solvent. The product was purified by flash column chromatography using silica gel and 2 % methanol in dichloromethane. The structures of derivatives were confirmed by LCMS and ¹H-NMR spectroscopy.

Structure A) yield 200mg (56%). ¹H NMR (500 MHz, DMSO) 11.31 (s, 1H, NH), 7.50 (d, 1H, 6-H), 6.82 (dd, 1H, 1'-H), 6.42 (dd, 1H, 3'-H), 5.91 (dd, 1H, 2'-H), 4.88 (s, 1H, 4'-H), 3.56 (m, 2H, 5'-H), 3.28 (s, 3H, OCH₃), 1.75 (s, 3H, CH₃).

Structure B) 67mg (18.7 %). ¹H NMR (500 MHz, DMSO) 7.56(s, 1H, 6-H), 6.88 (dt, 1H, 1'-H), 6.43 (dd, 1H, 3'-H), 5.90 (d, 1H, 2'-H), 4.89 (s, 1H, 4'-H), 3.56 (m, 2H, 5'-H), 3.27 (s, 3H, OCH₃), 3.18 (s, 3H, NCH₃), 1.8 (s, 3H, CH₃).

Structure C) 1g- scale yield was 0.4g solid (36 %). ¹H NMR(500 MHz, DMSO) 11.31 (s, 1H, NH), 7.56 (d, 1H, 6-H), 6.88 (dt, 1H, 1'-H), 6.43 (dd, 2H, 3'-H), 5.91 (m, 2H, 2'-H), 4.89(s, 1H, 4'-H), 6.43 (dd, 1H, 3'-H), 5.91 (d, 2H, 2'-H), 4.89 (s, 1H, 4'-H), 3.55(t, 2H, 5'-H), 3.27 (s, 3H, OCH₃), 3.18 (s, 3H, NCH₃), 1.8 (d, 3H, CH₃).

Structure D) oil (0.5g, 46 %). ¹H NMR (500 MHz, DMSO) 7.56 (d, 1H, 6-H), 6.88 (dt, 1H, 1'-H), 6.43 (dd, 2H, 3'-H), 5.91 (m, 2H, 2'-H), 4.89(s, 1H, 4'-H), 6.43 (dd, 1H, 3'-H), 5.91 (d, 2H, 2'-H), 4.89 (s, 1H, 4'-H), 3.55(t, 2H, 5'-H), 3.27 (s, 3H, OCH₃), 3.18 (s, 3H, NCH₃), 1.8 (d, 3H, CH₃).

Structure E) Reaction was complete in one hour. Yield 0.224g(55 %). ¹H NMR (500 MHz, DMSO) 7.81 (d, 1H, H₆), 6.23 (t, 1H, H_{4'}), 6.09 (d, 1H, H₅), 5.31 (t, 1H, H_{2'}), 3.70 (m, 2H, H_{6'}), 3.43 (dd, 1H, H_{5'b}), 3.34 (s, 3H, OCH₃), 3.08 (dd, 1H, H_{5'a}), 3.04 (s, 6H, N(CH₃)₂).

[00228] Example 2

[00229] In this Example, structures of unique NRTIs, also referred to as "Kamuvudines", are studied. A procedure for the synthesis of these Kamuvudines is described herein. Also provided is NMR and mass spectrometry data for these Kamuvudines and data regarding the biological activity of Kamuvudines.

[00230] Synthesis of 5'-O-alkyl substituted and of di-alkyl substituted Kamuvudines


[00231] To a suspension of nucleotide (1.5 m-mole) in dry THF (5 mL) was added NaH (4.5 m-mole) and the mixture was stirred for 10 minutes at room temperature under nitrogen. Alkyl Iodide (4.5 m-mole) was added in one portion to the mixture and stirred for 1-3h. The reaction was checked for completion by TLC and quenched by drop-wise addition of methanol. The mixture was neutralized with acetic acid and evaporated. The residue was suspended in dichloromethane and washed with aqueous NaHSO₃ solution, dried over MgSO₄ and the solvent was evaporated. The product was purified by flash column chromatography using silica gel using ethyl acetate/hexane as solvent. The structures of derivatives were confirmed by LCMS and ¹H-NMR spectroscopy.

[00232] Synthesis of asymmetric di-substituted Kamuvudines.

[00233] A) Synthesis of N-substituted nucleosides. To a suspension of nucleotide (1.5 m-mole) in dichloromethane (5 mL) was added NaH (1.5 m-mole) and the mixture was stirred for 10 minutes at room temperature under nitrogen. Alkyl Iodide (1.5 m-mole) was added in one portion to the mixture and stirred for 1-3h. The reaction was checked for completion by TLC. Wash the extract with brine and dry with anhydrous sodium sulfate. Evaporate solvent and purify the N-substituted product by flash chromatography.

[00234] B) To a suspension of N-substituted nucleotide (1.5 m-mole) in dichloromethane (5 mL) was added NaH (1.5 m-mole) and the mixture was stirred for 10 minutes at room temperature under nitrogen. Alkyl Iodide (1.5 m-mole) was added in one portion to the mixture and stirred for 1-3h. The reaction was checked for completion by TLC. Wash the extract with brine and dry with anhydrous sodium sulfate. Evaporate solvent and purify the di-substituted product by flash chromatography.

[00235] NMR and Mass Spectrometry data for Kamuvudines



1. a) O-Me-d4T

^1H NMR (400 MHz, DMSO-*d*6) δ 11.37 (s, 1H), 7.26 (q, $J = 1.3$ Hz, 1H), 6.85 (dt, $J = 3.6$, 1.7 Hz, 1H), 6.44 (dt, $J = 6.0$, 1.6 Hz, 1H), 6.05 (dt, $J = 6.1$, 1.8 Hz, 1H), 5.04 (s, 1H), 4.41 (t, $J = 2.7$ Hz, 2H), 3.17 (d, $J = 1.2$ Hz, 3H), 1.75 (d, $J = 1.3$ Hz, 3H). MS (ESI): $[\text{M} + \text{Na}]^+$ Mass calculated $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_4\text{Na}^+ = 261.23$, found = 261.2.

1. b) 2-Me-d4T

^1H NMR (400 MHz, DMSO-*d*6) δ 7.56 (q, $J = 1.2$ Hz, 1H), 6.89 (ddd, $J = 3.4$, 1.9, 1.4 Hz, 1H), 6.44 (dt, $J = 6.0$, 1.8 Hz, 1H), 5.91 (ddd, $J = 6.0$, 2.5, 1.4 Hz, 1H), 4.96 – 4.83 (m, 1H), 3.60 – 3.52 (m, 2H), 3.28 (s, 3H), 3.18 (s, 3H), 2.08 (s, 2H), 1.81 (d, $J = 1.2$ Hz, 3H). MS (ESI): $[\text{M} + \text{Na}]^+$ Mass calculated $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_4\text{Na}^+ = 275.28$, found 275.2.

1. c) 2-Et-d4T


^1H NMR (400 MHz, DMSO-*d*6) δ 7.50 (t, $J = 1.3$ Hz, 1H), 6.89 (dq, $J = 3.4, 1.5$ Hz, 1H), 6.44 (dt, $J = 5.9, 1.6$ Hz, 1H), 5.93 (ddt, $J = 6.0, 2.5, 1.4$ Hz, 1H), 4.90 (d, $J = 3.6$ Hz, 1H), 3.93 – 3.78 (m, 2H), 3.59 (td, $J = 3.1, 1.3$ Hz, 2H), 3.45 (qt, $J = 7.0, 1.5$ Hz, 3H), 1.80 (d, $J = 1.3$ Hz, 3H), 1.10 (tdd, $J = 7.0, 5.2, 1.3$ Hz, 6H). MS (ESI): $[\text{M}+\text{Na}]^+$ Mass calculated $\text{C}_{14}\text{H}_{20}\text{N}_2\text{O}_4\text{Na}^+ = 303.3$, found 303.2

1. d) N-Et d4T

^1H NMR (400 MHz, DMSO-*d*6) δ 7.69 (q, $J = 1.2$ Hz, 1H), 6.89 (dt, $J = 3.4, 1.7$ Hz, 1H), 6.41 (dt, $J = 6.0, 1.8$ Hz, 1H), 5.92 (ddd, $J = 6.0, 2.4, 1.4$ Hz, 1H), 5.01 (t, $J = 5.3$ Hz, 1H), 4.84 – 4.75 (m, 1H), 3.85 (qd, $J = 7.1, 1.8$ Hz, 2H), 3.60 (dd, $J = 5.3, 3.4$ Hz, 2H), 1.78 (d, $J = 1.2$ Hz, 3H), 1.09 (t, $J = 7.0$ Hz, 3H). MS (ESI): $[\text{M}+\text{Na}]^+$ Mass calculated $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_4\text{Na}^+ = 275.28$, found 275.2

1. e) O-Me N-Et d4T

^1H NMR (400 MHz, DMSO-*d*6) δ 7.55 (d, $J = 1.3$ Hz, 1H), 6.90 (dt, $J = 3.3, 1.7$ Hz, 1H), 6.45 (dt, $J = 6.0, 1.7$ Hz, 1H), 5.93 (ddd, $J = 6.1, 2.3, 1.4$ Hz, 1H), 4.91 (d, $J = 4.1$ Hz, 1H), 3.91 – 3.81 (m, 2H), 3.56 (dd, $J = 3.1, 1.5$ Hz, 2H), 3.28 (s, 3H), 1.81 (d, $J = 1.2$ Hz, 3H), 1.10 (t, $J = 7.0$ Hz, 3H). MS (ESI): $[\text{M}+\text{Na}]^+$ Mass calculated $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+ = 289.31$, found 289.2.



2. a) $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{H}$
 b) $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{CH}_3$
 c) $\text{R}_1 = \text{R}_2 = \text{CH}_2\text{CH}_3$

2. a) O-MeAZT

^1H NMR (400 MHz, DMSO-*d*6) δ 11.30 (s, 1H), 7.50 (q, $J = 1.1$ Hz, 1H), 6.82 (dt, $J = 3.3, 1.6$ Hz, 1H), 6.41 (dt, $J = 6.1, 1.7$ Hz, 1H), 5.91 (ddd, $J = 6.2, 2.5, 1.3$ Hz, 1H), 4.93 – 4.77 (m, 1H), 3.55 (d, $J = 3.1$ Hz, 2H), 3.28 (s, 3H), 1.75 (d, $J = 1.3$ Hz, 3H). MS (ESI): $[\text{M}+\text{H}]^+$, $\text{C}_{11}\text{H}_{15}\text{N}_3\text{O}_4^+$, calculated 282.26, found 282.2

2. b) 2-Me-AZT


^1H NMR (400 MHz, DMSO-*d*₆) δ 7.63 (q, $J = 1.2$ Hz, 1H, H6), 6.15 (t, $J = 6.4$ Hz, 1H, H1'), 4.43 (dt, $J = 7.3, 5.4$ Hz, 1H, H3'), 3.97 (dt, $J = 5.1, 4.1$ Hz, 1H, H4'), 3.67 – 3.50 (m, 2H, H5'), 3.35 (s, 3H, OCH₃), 3.17 (s, 3H, NCH₃), 2.46 – 2.27 (m, 2H, H2'), 1.85 (d, $J = 1.2$ Hz, 3H, CH₃).

MS (ESI): $[\text{M}+\text{H}]^+$ C₁₂H₁₈N₅O₄⁺, calculated = 296.29, found 296.2

2. c) 2-Et-AZT

^1H NMR (400 MHz, DMSO-*d*₆) δ 7.62 (t, $J = 1.2$ Hz, 1H, H6), 6.16 (t, $J = 6.4$ Hz, 1H, H1'), 4.43 (q, $J = 5.8$ Hz, 1H, H3'), 3.96 (q, $J = 4.4$ Hz, 1H, H4'), 3.83 (q, $J = 7.0$ Hz, 2H), 3.68 – 3.55 (m, 2H, H5'), 3.55 – 3.44 (m, 2H), 2.37 (dp, $J = 20.5, 7.0$ Hz, 2H, H2'), 1.84 (d, $J = 1.2$ Hz, 3H, CH₃), 1.15 (td, $J = 7.0, 1.1$ Hz, 3H), 1.08 (t, $J = 7.0$ Hz, 3H).

MS (ESI): $[\text{M}+\text{H}]^+$ calculated C₁₄H₂₂N₅O₄⁺ = 324.35, found 324.2.



3. a) R₁=R₂=R₃=CH₃
b) R₁=R₂=R₃=CH₂CH₃

3. a) 3-Me-3TC

^1H NMR (400 MHz, DMSO-*d*₆) δ 7.82 (d, $J = 7.8$ Hz, 1H), 6.23 (t, $J = 5.2$ Hz, 1H), 6.09 (d, $J = 7.8$ Hz, 1H), 5.31 (t, $J = 4.7$ Hz, 1H), 3.77 – 3.65 (m, 2H), 3.44 (dd, $J = 11.7, 5.5$ Hz, 1H), 3.34 (s, 3H), 3.09 (dd, $J = 11.7, 4.9$ Hz, 1H), 3.05 (s, 6H).

MS (ESI): $[\text{M}+\text{H}]^+$, C₁₁H₁₈N₃O₃S⁺ calculated 272.34, found 272.2

3. b) 3-Et-3TC

^1H NMR (400 MHz, DMSO-*d*₆) δ 7.89 – 7.77 (m, 1H), 6.22 (d, $J = 4.7$ Hz, 1H), 6.03 (d, $J = 8.2$ Hz, 1H), 5.29 (d, $J = 4.6$ Hz, 1H), 3.74 (d, $J = 4.7$ Hz, 2H), 3.60 – 3.48 (m, 4H, CH₂), 3.32 (s, 2H), 3.10 (d, $J = 12.1$ Hz, 1H), 1.18 – 1.01 (m, 9H, CH₃). MS (ESI): $[\text{M}+\text{H}]^+$,

C₁₄H₂₄N₃O₃S⁺ calculated 314.41, found 314.4

[00236] Characteristics of NRTIs and Kamuvudines

[00237] In some embodiments, as compared to the original NRTIs (d4T, 3TC, AZT), the Kamuvudines (modified NRTIs) have more desirable drug-like characteristics. For example, referring to Table 1 below, as compared to the NRTIs, the Kamuvudines have greater LogP values (greater than 0 and close to 1) and lower solubility in water. During certain types of compound release, such as in an intraocular sustained release drug delivery system, the greater LogP values and lower solubility of the Kamuvudines provide greater resident times (i.e., longer half-lives) in the vitreous humor and retina, as compared to the original NRTIs.

TABLE 1

Name	LogP	Solubility (mg/ml)
d4T	-0.23	106
Me-d4T	0.41	30
2Me-d4T	0.63	10
2Et-d4T	1.35	0.09
O-Me, N-Et-d4T	0.99	1.5
3TC	-1.1	64
TM-3TC	0.09	7
3Et-3TC	1.16	1.6
AZT	-0.41	16
2Me-AZT	0.45	0.94
2Et-AZT	1.17	0.01
LogP: Partition coefficient in 1-octanol.		
Solubility in Water pH 7.2 at 37 °C.		

[00238] Efficacy of NRTIs and Kamuvudines in cells

[00239] With reference to **FIGS. 64-73**, and **74-78**, compounds as disclosed herein inhibit Caspase-1 activation. Caspase-1 is the enzyme at the core of the inflammasome complex and is an important danger response signal and mediator of RPE cell death in AMD. **FIGS. 64-73** show that Kamuvudines dose-dependently inhibit Caspase-1 as determined by the iGluce luminescence assay in mouse J774 iGluce cells. Importantly, there was some difference between individual compounds in terms of the dose response curve, emphasizing the need to test each compound (with unique R group(s)) individually. Furthermore, Kamuvudines exhibited variable, incomplete inhibition of Caspase-1 activation, also suggesting that there are differences of compound activity within the class of Kamuvudines.

[00240] To obtain the data set forth in **FIGS. 64-73**, an iGluce assay was conducted (modified from Bartok et al. iGluce: a luciferase-based inflammasome and protease activity

reporter. Nature Methods 2013; 10(2):147-54). Briefly, 100,000 iGLuc cells per well were plated in a 96 well plate overnight. The next morning, media is aspirated from the plate and replaced with 75 μ L of serum free DMEM with drugs (NRTIs or modified NRTIs) for 30 min. After 30 minutes of drug exposure, 20 mM ATP (25 μ L) is added for a final concentration of 5 mM. 50 μ L of media from each well is collected and 50 μ L of coelenterazine 4.4 μ M is added to each sample, and luminescence is read immediately.

[00241] FIG. 64 shows that 3TC inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 3TC (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00242] FIG. 65 shows that 3Me-3TC inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 3Me-3TC (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00243] FIG. 66 shows that 3Et-3TC inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 3Et-3TC (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00244] FIG. 67 shows that AZT inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to AZT (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00245] FIG. 68 shows that 2Me-AZT inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 2Me-AZT (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00246] FIG. 69 shows that 2Et-AZT inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 2Et-AZT (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00247] FIG. 70 shows that d4T inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage

by Caspase-1 in mouse J774 iGLuc cells. Exposure to d4T (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00248] FIG. 71 shows that O-Me N-Et d4T inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to O-Me N-Et d4T (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00249] FIG. 72 shows that Me-d4T inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to Me-d4T (100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00250] FIG. 73 shows that 2Et-d4T inhibits Caspase-1 activation. ATP (5 mM) induces Caspase-1 activation, which is measured by luminescence monitoring of Luciferase cleavage by Caspase-1 in mouse J774 iGLuc cells. Exposure to 2Et-d4T (1 nM – 100 μ M) reduces Caspase-1 cleavage in a dose-dependent fashion. N=3.

[00251] As illustrated in FIGS. 70-73, compared to d4T, there was a greater reduction in inflammasome activation by the Kamuvudines (modified NRTIs). Specifically, d4T reduced inflammasome activation by about 35%, while O-Me, N-Et-d4T reduced inflammasome activation by about 55%, Me-d4T reduced inflammasome activation by about 70%, and 2Et-d4T reduced inflammasome activation by about 45%. Without wishing to be bound by theory, as each of the Kamuvudines provided a greater reduction in inflammasome activation as compared to the parent NRTI (i.e., d4T), it is believed that the Kamuvudines also provide increased blocking of retinal degeneration.

[00252] FIG. 74 shows that Kamuvudines block Caspase-1 activation induced by Alu RNA in primary human RPE cells, as monitored by western blotting. Alu RNA induced Caspase-1 activation in primary human RPE cells, monitored by western blotting, is reduced by 2Et-d4T (25 μ M), 2Me-AZT (25 μ M), O-Me N-Et d4T (25 μ M), d4T-ene (25-100 μ M), and TM-3TC (25-100 μ M). N=3-4.

[00253] *Alu* RNA is a toxic endogenous retroelement that accumulates in and causes death of the RPE in patients with dry AMD. FIG. 75, shows that Kamuvudines block Caspase-1 activation in primary human cells exposed to iron (Fe³⁺) ammonium citrate (FAC). FAC activates Caspase-1 via an *Alu* RNA intermediate, and induces NLRP3-dependent RPE degeneration (Gelfand et al. Cell Reports 2015). Fe(III) ammonium citrate (100 μ M)-induced Caspase-1 activation in primary human RPE cells, monitored by western

blotting, is reduced by TM-3TC (25 μ M), d4T-ene (25 μ M), 2Me-d4T (25 μ M), Me-AZT (25-100 μ M), and 2Me-AZT (25 μ M). N=3-4.

[00254] FIGS. 76-78, show that the NRTI 3TC blocks Caspase-1 activation induced by AMD-associated stressors (Complement protein C3a, ROS-generator paraquat, and amyloid beta) in primary human RPE cells. FIG. 76 shows that NRTIs reduce Complement-induced Caspase-1 activation in human RPE cells. Human C3a (100 nM)-induced Caspase-1 activation after LPS priming in primary human RPE cells, monitored by western blotting, is reduced by 3TC (25 μ M). N=3-4. FIG. 77 shows that NRTIs reduce Paraquat-induced Caspase-1 activation in human RPE cells. Paraquat (250 μ M)-induced Caspase-1 activation in primary human RPE cells, monitored by western blotting, is reduced by 3TC (25 μ M). N=3-4. FIG. 78 shows that NRTIs reduce Amyloid beta-induced Caspase-1 activation in human RPE cells. Oligomerize A β 1-40 peptide (0.5 μ M)-induced Caspase-1 activation in primary human RPE cells, monitored by western blotting, is reduced by 3TC (10-25 μ M). N=3-4.

[00255] Efficacy of NRTIs and Kamuvudines in mice

[00256] The efficacy of Kamuvudines in mouse models of dry and wet AMD is shown herein. With reference to FIGS. 79-87, compounds as disclosed herein reduce choroidal neovascularization (CNV) in a model of "wet AMD" and block RPE degeneration in a model of "dry AMD."

[00257] FIGS. 79 and 80 show that NRTIs and Kamuvudines are effective in the laser-induced model of choroidal neovascularization (CNV; wet AMD). FIG. 79 shows that compounds disclosed herein reduce choroidal neovascularization in a model of "wet AMD". Intravitreal administration of 3TC (0.55 nmol), ABC (0.64 nmol), or AZT (0.55 nmol) after laser injury reduced laser injury-induced CNV volume in wild-type mice. Injection of PBS or DMSO were vehicle controls. N=16. FIG. 80 shows that compounds disclosed herein reduce choroidal neovascularization (CNV) in a model of "wet AMD". Intravitreal administration of Me-d4T, O-Me-N-Et-d4T, 2Et-AZT or 3Et-3TC (0.14 nmol) after laser injury reduced choroidal neovascularization (CNV) volume in wild-type mice at day 7. Injection of DMSO was vehicle controls. N=16. Compared to NRTIs (FIG. 79), modified NRTIs (FIG. 80) are more potent (smaller dose required) at suppressing CNV and are more effective (greater degree of suppression achieved).

[00258] Without wishing to be bound by theory, it is believed that both the NRTIs and the Kamuvudines provide antiangiogenic effects in a P2X7-dependent manner, which reduces

CNV. Specifically, intravitreal injection of the NRTIs or the Kamuvudines suppressed laser-induced CNV in wild-type mice as compared to PBS or DMSO, respectively, while intravitreal injection of the NRTIs did not suppress the laser-induced CNV in *P2rx7^{-/-}* mice. Additionally, intravitreal injection of the NRTIs suppressed laser-induced CNV in *Nlrp3^{-/-}* mice, indicating that the antiangiogenic effects are *Nlrp3*-independent. The P2X7 inhibition and/or angio-inhibitory effects of the NRTIs and Kamuvudines is also believed to be effective in treating other diseases, including, but not limited to, blocking tumor growth and/or treating graft-versus-host disease.

[00259] **FIGS. 81 and 82** show that, compared to original NRTIs, Kamuvudines have increased effectiveness and potency in treating existing neovascular disease. JR5558 mice develop spontaneous choroidal neovascularization (CNV) and are an animal model of wet / neovascular age-related macular degeneration (AMD). The activity of the CNV lesions can be monitored using fluorescein angiography to assess the degree of dye leakage from the lesions, as is done in humans with this disease. **FIGS. 81 and 82** are representative images from two JR5558 mice (N=8). The first and third row of **FIGS. 81 and 82** show time dependent dye leakage from pre-existing CNV lesions in the left eye (first row) and right eye (third row) of a first and second JR5558 mouse, respectively. The second row of **FIGS. 81 and 82** show time dependent dye leakage in the left eye after a single intravitreal administration of 125 ng of 3TC, and the fourth row shows time dependent dye leakage in the right eye after a single intravitreal administration of 62.5 ng of 3-Me-3TC. As seen in rows two and four, both 3TC and 3-Me-3TC suppress the activity of pre-existing CNV lesions 3 days after administration (i.e., reduce their dye leakage). Additionally, compared to the original NRTI (3TC), the Kamuvudine (i.e., 3-Me-3TC) provides a greater reduction in CNV lesion leakage (i.e., is more effective) at lower doses (i.e., is more potent).

[00260] In models of dry AMD, in **FIGS. 83-86**, Kamuvudines are shown to block *Alu*-induced RPE degeneration, as monitored by fundus photography and ZO-1 flat mount staining of RPE, in a model of dry AMD.

[00261] **FIG. 83** shows that compounds disclosed herein block *Alu* RNA-induced RPE degeneration in a model of "dry AMD". Subretinal injection of *Alu* RNA (0.3 µg) induces RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row) in wild-type mice. Intraperitoneal administration of 3Me-3TC (25 mg/kg, twice daily for 6 days after *Alu* RNA injection) protects against RPE degeneration, as seen on fundus photos (Top; smaller area of whitish

area of discoloration) and ZO-1 immunostained RPE flat mounts (Bottom; more hexagonal, tessellated appearance). Bottom panels show fundus photographs that demonstrate that intraperitoneal administration of O-Me N-Et d4T (25 mg/kg, twice daily for 6 days after Alu RNA injection) protects against Alu RNA-induced RPE degeneration in wild-type mice. Image representative of 6 experiments.

[00262] FIG. 84 shows that 3Me-3TC disclosed herein block pAlu-induced RPE degeneration in a model of “dry AMD”. Subretinal injection of a plasmid encoding Alu (pAlu) induces RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row) in wild-type mice. Intraperitoneal administration of 3Me-3TC (25 mg/kg, twice daily for 6 days after pAlu injection) protects against RPE degeneration, as seen on fundus photos (Top) and ZO-1 immunostained RPE flat mounts (Bottom). Image representative of 6 experiments.

[00263] FIG. 85 shows that 3Et-3TC blocks pAlu-induced RPE degeneration in a model of “dry AMD”. Subretinal injection of a plasmid encoding Alu (pAlu) induces RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row) in wild-type mice. Intraperitoneal administration of 3Et-3TC (25 mg/kg, twice daily for 6 days after pAlu injection) protects against RPE degeneration, as seen on fundus photos (Top) and ZO-1 immunostained RPE flat mounts (Bottom). Image representative of 6 experiments.

[00264] FIG. 86 shows that compounds disclosed herein block pAlu-induced RPE degeneration in a model of “dry AMD”. Subretinal injection of a plasmid encoding Alu (pAlu) induces RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row) in wild-type mice. Intraperitoneal administration of 2Et-d4T or 2Et-AZT (25 mg/kg, twice daily for 6 days after pAlu injection) protects against RPE degeneration, as seen on fundus photos. Image representative of 6 experiments.

[00265] In FIGS. 87-89, Kamuvudines are shown to be effective in blocking RPE degeneration after intraocular injection of poly I:C, amyloid beta, and iron.

[00266] FIG. 87 shows that compounds disclosed herein block poly IC-induced RPE degeneration in a model of “dry AMD”. Poly IC (0.2 µg) administered into the subretinal space of wild-type mice induces RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row). Intravitreal administration of Me-d4T or 2-Me-d4T (0.14 mmol) (after poly IC injection) blocks this

degeneration (measured 7 days after poly IC). Top row shows representative fundus photographs. Bottom row shows representative ZO-1 immunostained RPE flat mounts. N=4-6.

[00267] **FIG. 88** shows that compounds disclosed herein block Amyloid beta-induced RPE degeneration in a model of "dry AMD". Oligomerized Amyloid beta 1-40 peptide (0.83 μ mol) was injected into the subretinal space of mice to induce RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row). Intraperitoneal administration of 3TC or K-2 (2Me-d4T) on days 1 to 6 (25 mg/kg) blocked the development of RPE degeneration on day 7. Top row shows color fundus photographs. Bottom row show ZO-1 stained RPE flat mounts.

[00268] **FIG. 89** shows that compounds disclosed herein block Iron-induced RPE degeneration in a model of "dry AMD". Fe(III) ammonium citrate (3 nM) was injected into the subretinal space of mice to induce RPE degeneration (whitish yellow region on color fundus photograph (top row) and disorganization of hexagonal array (bottom row). Intraperitoneal administration of d4T, K-1 (Me-d4T), or K-2 (2Me-d4T) on days 1 to 6 (25 mg/kg) blocked the development of RPE degeneration on day 7 compared to vehicle treatment. Top row shows color fundus photographs. Bottom row show ZO-1 stained RPE flat mounts.

[00269] **Safety/Toxicity of NRTIs vs Kamuvudines in mice and cells**

[00270] Safety and toxicity of the compounds was also studied. **FIG. 90** shows that NRTIs are toxic to the retina after intravitreal injection. Surprisingly and unexpectedly, adding a single R substitution to NRTIs eliminated this toxicity: **FIG. 91** shows that intravitreal injection of the same dose of Kamuvudines is not toxic, indicating that they are safer than NRTIs for intraocular administration. Furthermore, **FIG. 92** we shows that Kamuvudines are safe in that their intravitreal administration does not induce anatomical disruption of the retina.

[00271] **FIG. 90** shows that known NRTIs can cause retinal toxicity. Intravitreal injection of d4T, AZT, or 3TC (0.56 nmol) in mice induced areas of retinal degeneration (red arrowheads) retinal toxicity. Representative color fundus photograph images shown (N=8). These data indicate that, NRTIs could have adverse effects following intraocular administration.

[00272] FIG. 91 shows that compounds disclosed herein are not toxic to the retina. Intravitreal injection of Kamuvudines 1-9 (2.8 nmol) in mice did not induce retinal toxicity. Representative color fundus photograph images shown (N=8). These data indicate that, unlike NRTIs, Kamuvudines are safer for intraocular administration.

[00273] FIG. 92 also shows that compounds disclosed herein are not toxic to the retina. Intravitreal injection of Kamuvudines 1-5 (2.8 nmol) in mice did not induce any anatomical disruption of the retina (H&E staining – top row) or changes in thickness of the various layers of the retina (ILM: internal limiting membrane; OLM: outer limiting membrane; IPL: inner plexiform layer; INL: inner nuclear layer; ONL: outer nuclear layer; IS: inner segments; OS: outer segments). N=8. These data indicate that, unlike NRTIs, Kamuvudines are safer for intraocular administration even at very high concentrations.

[00274] Finally, FIGS. 93 and 94 show that Kamuvudines, lack “off-target” polymerase inhibition of NRTIs. That is, the substitution of an R group on NRTIs completely changed their activity towards polymerase inhibition.

[00275] FIG. 93 shows that NRTIs, but not Kamuvudines, blocked mitochondrial DNA copy number in primary human RPE cells in culture. NRTIs deplete mitochondrial (mt) DNA by competing with endogenous nucleotides for DNA polymerase gamma; mtDNA depletion is thought to be largely responsible for many side effects associated with NRTI use. There were some differences between Kamuvudines in the rescue of mtDNA levels, indicating the need to test each modified compound individually. The graphs show the relative quantity of mtDNA in primary human RPE cells treated with NRTIs (d4T, 3TC, or AZT) or modified NRTIs (Me-d4T, 2Me-d4T, TM-3TC Me-AZT, or 2Me-AZT), relative to vehicle treatment (DMSO, a.k.a “No Tx”) at a concentration of 50 μ M for all drugs. DNA was collected after four days in cell culture with exposure to drug. Quantitative polymerase chain reaction was performed for mtDNA and normalized to genomic DNA sequence. D4T, 3TC, and AZT exhibit mtDNA depletion. Modified versions of d4T and AZT do not exhibit mtDNA depletion. N = 3-4/group, error bars are S.E.M. These data indicate that NRTIs can cause mitochondrial toxicity, whereas most modified NRTIs do not do cause mitochondrial toxicity. As mitochondrial toxicity has been blamed for myopathy, peripheral neuropathy, and hepatic steatosis with lactic acidosis observed in patients taking NRTIs, and the modified NRTIs do not cause mitochondrial toxicity, it is expected that the modified NRTIs are safer (i.e., decrease or eliminate mitochondrial toxicity) than the original NRTIs.

[00276] FIG. 94 shows the results of a L1 retrotransposition assay, in which an EGFP reporter is expressed only upon successful reverse transcription and integration of human

LINE-1 retrotransposon. NRTIs, but not Kamuvudines, blocked L1 retrotransposition, indicating that they do not block RNA-dependent DNA polymerase activity. These findings pave way for the rational re-design and improvement of nucleoside analogs as novel therapeutics. The enhanced green fluorescent protein (EGFP) cell culture L1 retrotransposition assay was performed in HeLa cells. Cells were transfected with a plasmid expressing an active L1 sequence tagged with an EGFP reporter in the presence of vehicle (RPS) or in the presence of NRTIs (d4T, AZT, or 3TC) or methoxy-NRTIs (Me-d4T, 2Me-d4T, Me-AZT, 2Me-AZT, 3Me-3TC, 2Et-d4T, 2Et-AZT, or 3Et-3TC). Transfected cells were selected in puromycin. 7 days after transfection, cells that underwent retrotransposition (EGFP-positive) were assayed by flow cytometry. Cells were gated based on background fluorescence of plasmid JM111, which has two point mutations in L1-ORF1 that abolish retrotransposition. Data are normalized with RPS set to 1. These data indicate that NRTIs interfere with endogenous L1 activity whereas the modified NRTIs would not interfere with this natural L1 activity of the cell. 3Et-3TC appears to have some residual interference with natural L1 activity, whereas the other Kamuvudines (modified NRTIs) have no effect on L1 activity.

[00277] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference, including the references set forth in the following list:

REFERENCES

1. International Patent Application No. PCT/US11/38753.
2. International Patent Application No. PCT/US12/46928.
3. U.S. Provisional Patent Application Serial No. 61/586,427.
4. U.S. Provisional Patent Application Serial No. 61/780,105.
5. Adinolfi, E., Callegari, M.G., Ferrari, D., Bolognesi, C., Minelli, M., Wieckowski, M.R., Pinton, P., Rizzuto, R., and Di Virgilio, F. (2005). Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. *Mol Biol Cell* 16, 3260-3272.
6. Agarwal, H.K., Loethan, K., Mandal, D., Doncel, G.F., and Parang, K. (2011). Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine. *Bioorg Med Chem Lett* 21, 1917-1921.
7. Ahmad, R., Sindhu, S.T., Toma, E., Morisset, R., and Ahmad, A. (2002). Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. *J Virol* 76, 12448-12456.

8. Ambati, J., Ambati, B.K., Yoo, S.H., Ianchulev, S., and Adamis, A.P. (2003). Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. *Surv Ophthalmol* 48, 257-293.
9. Ambati, J., and Fowler, B.J. (2012). Mechanisms of age-related macular degeneration. *Neuron* 75, 26-39.
10. Balzarini, J., Herdewijn, P., and De Clercq, E. (1989). Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. *J Biol Chem* 264, 6127-6133.
11. Batzer, M.A., and Deininger, P.L. (2002). Alu repeats and human genomic diversity. *Nat Rev Genet* 3, 370-379.
12. Cheewatrakoolpong, B., Gilchrest, H., Anthes, J.C., and Greenfeder, S. (2005). Identification and characterization of splice variants of the human P2X7 ATP channel. *Biochem Biophys Res Commun* 332, 17-27.
13. Cruz, C.M., Rinna, A., Forman, H.J., Ventura, A.L., Persechini, P.M., and Ojcius, D.M. (2007). ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. *J Biol Chem* 282, 2871-2879.
14. David, D., Chevrier, D., Treilhou, M.P., Joussemet, M., Dupont, B., Theze, J., and Guesdon, J.L. (2000). IL-18 underexpression reduces IL-2 levels during HIV infection: a critical step towards the faulty cell-mediated immunity? *Aids* 14, 2212-2214.
15. Dewannieux, M., Esnault, C., and Heidmann, T. (2003). LINE-mediated retrotransposition of marked Alu sequences. *Nat Genet* 35, 41-48.
16. Dridi, S., Hirano, Y., Tarallo, V., Kim, Y., Fowler, B.J., Ambati, B.K., Bogdanovich, S., Chiodo, V.A., Hauswirth, W.W., Kugel, J.F., *et al.* (2012). ERK1/2 activation is a therapeutic target in age-related macular degeneration. *Proc Natl Acad Sci U S A* 109, 13781-13786.
17. Ferrara, J.L., Levine, J.E., Reddy, P., and Holler, E. (2009). Graft-versus-host disease. *Lancet* 373, 1550-1561.
18. Garcia-Marcos, M., Fontanils, U., Aguirre, A., Pochet, S., Dehaye, J.P., and Marino, A. (2005). Role of sodium in mitochondrial membrane depolarization induced by P2X7 receptor activation in submandibular glands. *FEBS Lett* 579, 5407-5413.
19. Hazleton, J.E., Berman, J.W., and Eugenini, E.A. (2012). Purinergic receptors are required for HIV-1 infection of primary human macrophages. *J Immunol* 188, 4488-4495.
20. Hentze, H., Lin, X.Y., Choi, M.S., and Porter, A.G. (2003). Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. *Cell Death Differ* 10, 956-968.
21. Humphreys, B.D., Rice, J., Kertesz, S.B., and Dubyak, G.R. (2000). Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. *J Biol Chem* 275, 26792-26798.
22. Iannello, A., Boulassel, M.R., Samarani, S., Tremblay, C., Toma, E., Routy, J.P., and Ahmad, A. (2010). HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. *J Infect Dis* 201, 608-617.
23. Jankovic, D., Ganesan, J., Bscheider, M., Stickel, N., Weber, F.C., Guarda, G., Follo, M.,

- Pfeifer, D., Tardivel, A., Ludigs, K., *et al.* (2013). The Nlrp3 inflammasome regulates acute graft-versus-host disease. *J Exp Med* 210, 1899-1910.
24. Kahlenberg, J.M., and Dubyak, G.R. (2004). Mechanisms of caspase-1 activation by P2X7 receptor-mediated K⁺ release. *Am J Physiol Cell Physiol* 286, C1100-1108.
 25. Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B.D., Fowler, B.J., Cho, W.G., Kleinman, M.E., Ponicsan, S.L., Hauswirth, W.W., Chiodo, V.A., *et al.* (2011). DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. *Nature* 471, 325-330.
 26. Kerur, N., Hirano, Y., Tarallo, V., Fowler, B.J., Bastos-Carvalho, A., Yasuma, T., Yasuma, R., Kim, Y., Hinton, D.R., Kirschning, C.J., *et al.* (2013). TLR-Independent and P2X7-Dependent Signaling Mediate Alu RNA-Induced NLRP3 Inflammasome Activation in Geographic Atrophy. *Invest Ophthalmol Vis Sci* 54, 7395-7401.
 27. Kubes, P., and Mehal, W.Z. (2012). Sterile inflammation in the liver. *Gastroenterology* 143, 1158-1172.
 28. Lewis, W., Day, B.J., and Copeland, W.C. (2003). Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. *Nat Rev Drug Discov* 2, 812-822.
 29. Mariathasan, S., Newton, K., Monack, D.M., Vucic, D., French, D.M., Lee, W.P., Roose-Girma, M., Erickson, S., and Dixit, V.M. (2004). Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. *Nature* 430, 213-218.
 30. Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W.P., Weinrauch, Y., Monack, D.M., and Dixit, V.M. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 440, 228-232.
 31. Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* 10, 417-426.
 32. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 440, 237-241.
 33. McDonald, B., Pittman, K., Menezes, G.B., Hirota, S.A., Slaba, I., Waterhouse, C.C., Beck, P.L., Muruve, D.A., and Kubes, P. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. *Science* 330, 362-366.
 34. Nakahira, K., Haspel, J.A., Rathinam, V.A., Lee, S.J., Dolinay, T., Lam, H.C., Englert, J.A., Rabinovitch, M., Cernadas, M., Kim, H.P., *et al.* (2011). Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol* 12, 222-230.
 35. Nykanen, A., Haley, B., and Zamore, P.D. (2001). ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* 107, 309-321.
 36. Ostertag, W., Roesler, G., Krieg, C.J., Kind, J., Cole, T., Crozier, T., Gaedicke, G., Steinheider, G., Kluge, N., and Dube, S. (1974). Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. *Proc Natl Acad Sci U S A* 71, 4980-4985.
 37. Pelegrin, P., and Surprenant, A. (2006). Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. *Embo J* 25, 5071-5082.
 38. Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., and Tschopp, J. (2007). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. *Cell Death Differ* 14, 1583-1589.


39. Qu, Y., Misaghi, S., Newton, K., Gilmour, L.L., Louie, S., Cupp, J.E., Dubyak, G.R., Hackos, D., and Dixit, V.M. (2011). Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. *J Immunol* 186, 6553-6561.
40. Riteau, N., Baron, L., Villeret, B., Guillou, N., Savigny, F., Ryffel, B., Rassendren, F., Le Bert, M., Gombault, A., and Couillin, I. (2012). ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. *Cell Death Dis* 3, e403.
41. Sorge, R.E., Trang, T., Dorfman, R., Smith, S.B., Beggs, S., Ritchie, J., Austin, J.S., Zaykin, D.V., Vander Meulen, H., Costigan, M., *et al.* (2012). Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. *Nat Med* 18, 595-599.
42. Stylianou, E., Bjerkeli, V., Yndestad, A., Heggelund, L., Waehre, T., Damas, J.K., Aukrust, P., and Froland, S.S. (2003). Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. *Clin Exp Immunol* 132, 462-466.
43. Surprenant, A., Rassendren, F., Kawashima, E., North, R.A., and Buell, G. (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* 272, 735-738.
44. Tarallo, V., Hirano, Y., Gelfand, B.D., Dridi, S., Kerur, N., Kim, Y., Cho, W.G., Kaneko, H., Fowler, B.J., Bogdanovich, S., *et al.* (2012). DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88. *Cell* 149, 847-859.
45. Wilhelm, K., Ganesan, J., Muller, T., Durr, C., Grimm, M., Beilhack, A., Krempl, C.D., Sorichter, S., Gerlach, U.V., Juttner, E., *et al.* (2010). Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. *Nat Med* 16, 1434-1438.
46. Yamin, T.T., Ayala, J.M., and Miller, D.K. (1996). Activation of the native 45-kDa precursor form of interleukin-1-converting enzyme. *J Biol Chem* 271, 13273-13282.
47. Fowler, *et al.* (2014) Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. *Science* 346: 6212, 1000-1003.

[00278] One of ordinary skill in the art will recognize that additional embodiments or implementations are possible without departing from the teachings of the present disclosure or the scope of the claims which follow. This detailed description, and particularly the specific details of the exemplary embodiments and implementations disclosed herein, is given primarily for clarity of understanding, and no unnecessary limitations are to be understood therefrom, for modifications will become obvious to those skilled in the art upon reading this disclosure and may be made without departing from the spirit or scope of the claimed invention.

CLAIMS

What is claimed is:

1. A compound having the structure



R_1 is selected from covalent bond, H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxyl, acyloxyl, and acylamino;

R_2 is selected from H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxyl, acyloxyl, and acylamino;

R_4 is selected from H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxyl, acyloxyl, and acylamino;

R_5 is selected from C, CH, and S;

R_6 is selected from the group consisting of H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxyl, acyloxyl, and acylamino; and

R_7 is selected from the group consisting of H, alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxyl, acyloxyl, and acylamino.


2. The compound of claim 1, wherein R_1 is selected from the group consisting of ethyl, butyl, propyl, 2-methylpropyl, and t-butyl.

3. The compound of claim 1, wherein R_1 is selected from the group consisting of covalent bond, H and $-CH_3$.


4. The compound of any one of claims 1-3, wherein R_2 is selected from the group consisting of ethyl, butyl, propyl, 2-methylpropyl, and t-butyl.

5. The compound of any one of claims 1-3, wherein R_2 is $-N(R_3)_2$, where each R_3 is independently selected from the group consisting of alkyl, substituted alkyl, branched alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino.
6. The compound of claim 5, wherein each R_3 is independently selected from the group consisting of H, CH_3 , ethyl, butyl, t-butyl, isobutyl, propyl, 2-methylpropyl, isopropyl, pentyl, and hexyl.
7. The compound of any of claims 1-6, wherein R_4 is selected from the group consisting of $-CH_3$ and ethyl.
8. The compound of any of claims 1-7, wherein R_5 is selected from the group consisting of ethyl, butyl, propyl, 2-methylpropyl, and t-butyl.
9. The compound of any of claims 1-7, wherein R_6 is selected from the group consisting of $-N=N^+=NH$ and N_3 .
10. The compound of any of claims 1-9, wherein R_7 is selected from the group consisting of ethyl, butyl, propyl, 2-methylpropyl, and t-butyl.
11. The compound of any of claims 1-9, wherein R_7 is selected from the group consisting of $-CH_2-O-CH_3$, $-CH_3$, $=CH_2$, $-CH_2-NH_2$, and $-CH_2-N=N^+=NH$.
12. The compound of any of claims 1-9, wherein R_7 is $-CH_2-O-R_8$, wherein R_8 is selected from the group consisting of alkyl, substituted alkyl, alkylene, acyl, alkoxy, acyloxy, and acylamino.
13. The compound of claim 12, wherein R_8 is selected from the group consisting of $-CH_3$, ethyl, propyl, 2-methylpropyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, and hexyl.
14. The compound of any of claims 1-13, wherein the compound is a nucleoside reverse transcriptase inhibitor (NRTI).


15. The compound of claim 14, wherein the compound is a phosphorylation-incompetent nucleoside analog of the nucleoside reverse transcriptase inhibitor (NRTI).
16. A pharmaceutically acceptable salt of the compound of any one of claims 1-15.
17. A compound having a structure selected from the group consisting of:




18. A compound having a structure selected from the group consisting of:




19. A compound having a structure selected from the group consisting of:






2-isopropyl-d4T




O-isopropyl-d4T

, and a pharmaceutically acceptable salt thereof.


20. A compound having a structure selected from the group consisting of:




2-Me-AZT




O-Me-AZT




2-Et-AZT




O-Et-AZT




2-Propyl-AZT




O-Propyl-AZT




2-Butyl-AZT




O-Butyl-AZT




2-isobutyl-AZT




O-isobutyl-AZT




2-tert-butyl-AZT




O-tert-butyl-AZT



3-Me-3TC




3-Et-3TC



3-Propyl-3TC



3-Isopropyl-3TC




3-Butyl-3TC




3-Isobutyl-3TC



3-Tert-butyl-3TC



O-isopropyl-AZT




2-isopropyl-AZT

, and a pharmaceutically acceptable salt thereof.


21. A compound having a structure selected from the group consisting of:



3tc-C6-4,1,1




3tc-C6-4*,1,1




3tc-C6-4**,1,1




3tc-C6-4**,2,0



3tc-C6-5,1,0




3tc-C6-4,2,0




3tc-C6-3,3,0




3tc-C6-2,4**,0






3tc-C6-4*,2,0




3tc-C6-3*,3*,0




3tc-C6-2,4*,0







3tc-C7-1,2,4*




3tc-C7-1,2,4**




3tc-C7-2,2,3*




3tc-C7-2,2,3




3tc-C7-3,1,3




3tc-C7-3,2,2




3tc-C7-4,0,3




3tc-C7-4**,0,3




3tc-C7-3*,1,3*




3tc-C7-3*,2,2



3tc-C7-4**,1,2



3tc-C7-4,1,2



22. A pharmaceutical composition comprising the compound of any one of claims 1-21 and a pharmaceutically acceptable carrier.

23. A method for treating retinal damage, comprising:
administering an effective amount of a compound of any one of claims 1-21 or a composition of claim 22 to a subject in need thereof.

24. A method for inhibiting inflammasome activation by Alu RNA associated with a cell, comprising: administering an effective amount of a compound of any one of claims 1-21 or a composition of claim 22 to a subject in need thereof.

25. The method of claim 24, wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.

26. A method for reducing ATP-induced permeability of a cell, comprising: administering an effective amount of a compound of any one of claims 1-21 or a composition of claim 22 to a subject in need thereof.

27. A method for reducing an amount of mitochondrial reactive oxygen species in a cell, comprising administering an effective amount of a compound of any one of claims 1-21 or a composition of claim 22 to a subject in need thereof.

28. The method of any one of claims 23-27, wherein the cell is selected from the group consisting of a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, and combinations thereof.

29. A method of treating a condition selected from conditions associated with retinal damage and/or degradation including dry age related macular degeneration (AMD) and wet AMD, various forms of arthritis, including rheumatoid arthritis and reactive arthritis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, Duchenne muscular dystrophy, graft-versus-host disease, chronic pain, proliferative vitreoretinopathy, glaucoma, multiple sclerosis, bipolar disorder, major depressive disorder, renal fibrosis, nephritis, pulmonary fibrosis, Huntington's disease, osteoporosis, chronic lymphocytic leukemia, anxiety disorders, pulmonary tuberculosis, osteoporosis in post-menopausal women and fracture patients, systemic lupus erythematosus, discoid lupus erythematosus, chronic inflammatory and neuropathic pain, autosomal dominant polycystic kidney disease, spinal cord injury, Alzheimer's disease, neuropathic pain, hypertension, varicose veins, type I diabetes, type II diabetes, gout, autoimmune hepatitis, graft vascular injury, atherosclerosis, thrombosis, metabolic syndrome, salivary gland inflammation, traumatic brain injury, ischemic heart disease, ischemic stroke, Parkinson's disease, melanoma, neuroblastoma, prostate, breast, skin, and thyroid cancers, tubular early gastric cancer, neuroendocrine cancer, mucoid colon cancer, colon cancer, high-grade urothelial carcinoma, kidney clear cell carcinoma, undifferentiated ovary carcinoma, papillary intracystic breast carcinoma, gram negative sepsis, infectious *Pseudomonas aeruginosa*, *Vibrio cholera*, *Legionella spp.*, *Francisella spp.*, and *Leishmania spp.*, *Chlamydia spp.*, cryopyrinopathies; keratitis, acne vulgaris, Crohn's disease, ulcerative colitis, insulin resistance, obesity, hemolytic-uremic syndrome, polyoma virus infection, immune complex renal disease, acute tubular injury, lupus nephritis,

familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease, chronic infantile neurologic cutaneous and articular autoinflammatory diseases, renal ischemia-perfusion injury, glomerulonephritis, cryoglobulinemia, systemic vasculitides, IgA nephropathy, malaria, helminth parasites, septic shock, allergic asthma, hay fever, drug-induced lung inflammation, contact dermatitis, leprosy, *Burkholderia cenocepacia* infection, respiratory syncytial virus infection, psoriasis, scleroderma, cystic fibrosis, syphilis, Sjögren's syndrome, inflammatory joint disease, non-alcoholic fatty liver disease, cardiac surgery (peri-/post-operative inflammation), acute and chronic organ transplant rejection, acute and chronic bone marrow transplant rejection, tumor angiogenesis, amyotrophic lateral sclerosis, and autism spectrum disorder comprising administering an effective amount of a compound of any one of claims 1-21 or a composition of claim 22 to a subject in need thereof.




FIG. 1




FIG. 2




FIG. 3




FIG. 4

3 / 58




FIG. 5




FIG. 6

5 / 58




FIG. 9




FIG. 10




FIG. 11




FIG. 12

7 / 58




FIG. 13







FIG. 14


8 / 58



pUC19



pAluA



pUC19 + d4T

pAluA + d4T

FIG. 15

9 / 58




FIG. 16




FIG. 17

10 / 58




FIG. 18




FIG. 19

11 / 58




FIG. 20




FIG. 21

12 / 58




FIG. 22




FIG. 23

13 / 58




FIG. 24




FIG. 25

15 / 58




FIG. 25 (continued)




FIG. 26





FIG. 27



19 / 58




FIG. 29




FIG. 30




FIG. 31




FIG. 32

21 / 58




FIG. 33



FIG. 34




FIG. 35

23 / 58




FIG. 36




FIG. 37

24 / 58




FIG. 38




FIG. 39




FIG. 40




FIG. 40 (Continued)




FIG. 41






FIG. 42

**FIG. 43****FIG. 44**

29 / 58






FIG. 45



FIG. 47

**FIG. 48****FIG. 49**

33 / 58




FIG. 50




FIG. 51




FIG. 52




FIG. 53

35 / 58




FIG. 54




FIG. 55

36 / 58




FIG. 56




FIG. 57

37 / 58




FIG. 58




FIG. 59

38 / 58




FIG. 60




FIG. 61

39 / 58




FIG. 62

40 / 58




FIG. 63

iGluc cell luminescence assay




FIG. 64

41 / 58

iGluc cell luminescence assay




FIG. 65

iGluc cell luminescence assay




FIG. 66

42 / 58

iGluc cell luminescence assay




FIG. 67

iGluc cell luminescence assay




FIG. 68

43 / 58

iGluc cell luminescence assay




FIG. 69

iGluc cell luminescence assay




FIG. 70

44 / 58

iGluc cell luminescence assay




FIG. 71

iGluc cell luminescence assay




FIG. 72

45 / 58

iGluc cell luminescence assay




FIG. 73

46 / 58




FIG. 74

47 / 58







FIG. 75

**FIG. 76****FIG. 77****FIG. 78**

49 / 58




FIG. 79




FIG. 80

50 / 58




FIG. 81




FIG. 82

51 / 58






FIG. 83

**FIG. 84****FIG. 85**

53 / 58






Fundus
photopAlu +
VehiclepAlu +
2Et-d4TpAlu +
2Et-AZT



FIG. 86

Poly IC +

Vehicle



Me-d4T



2-Me-d4T





FIG. 87

54 / 58


Oligo-A β + VehicleOligo-A β + 3TCOligo-A β + K-2

FIG. 88

Vehicle

Iron+Vehicle

Iron + d4T

Iron + K-1

Iron + K-2




FIG. 89

55 / 58




FIG. 90




FIG. 91

56 / 58




FIG. 92

57 / 58




FIG. 93




FIG. 94

+ PBS

+ Alu RNA




FIG. 1